

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68645 A2

- (51) International Patent Classification⁷: C07D 417/00
- (21) International Application Number: PCT/US01/08332
- (22) International Filing Date: 14 March 2001 (14.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/189,694 15 March 2000 (15.03.2000) US
- (71) Applicant (for all designated States except US): AXYS PHARMACEUTICALS, INC. [US/US]; 180 Kimball Way, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PALMER, James, T. [US/US]; 131 Koch Road, Corte Madera, CA 94925 (US). SETTI, Eduardo, L. [CA/US]; 804 North Delaware Street, San Mateo, CA 94401 (US). TIAN, Zong-Qiang [CN/US]; 5029 Xavier Common, Fremont, CA 94555 (US). VENKATRAMAN, Shankar [IN/US]; 2979 Garden Creek Circle, Pleasanton, CA 94588 (US). WANG, Dan-Xiong [CN/US]; 722 Edgewater Boulevard #300, Foster City, CA 94404 (US).
- (74) Agents: MONTGOMERY, Wayne, W. et al.; Axys Pharmaceuticals, Inc., 180 Kimball Way, South San Francisco, CA 94080 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/68645 A2

(54) Title: NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS

(57) Abstract: The present invention relates to novel *N*-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and *N*-oxides thereof, their uses as therapeutic agents and the methods of their making.

NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS

THE INVENTION

5 This application relates to compounds and compositions for treating diseases associated with cysteine protease activity, particularly diseases associated with activity of cathepsins B, K, L or S.

DESCRIPTION OF THE FIELD

10 Cysteine proteases represent a class of peptidases characterized by the presence of a cysteine residue in the catalytic site of the enzyme. Cysteine proteases are associated with the normal degradation and processing of proteins. The aberrant activity of cysteine proteases, e.g., as a result of increase expression or enhanced activation, however, may
15 have pathological consequences. In this regard, certain cysteine proteases are associated with a number of disease states, including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, periodontal disease, metachromatic leukodystrophy and others. For example, increased cathepsin B levels and redistribution of the enzyme are found in tumors; thus, suggesting a role for the enzyme in tumor invasion
20 and metastasis. In addition, aberrant cathepsin B activity is implicated in such disease states as rheumatoid arthritis, osteo arthritis, pneumocystis carinii, acute pancreatitis, inflammatory airway disease and bone and joint disorders.

25 The prominent expression of cathepsin K in osteoclasts and osteoclast-related multinucleated cells and its high collagenolytic activity suggest that the enzyme is involved in osteoclast-mediated bone resorption and, hence, in bone abnormalities such as occurs in osteoporosis. In addition, cathepsin K expression in the lung and its elastinolytic activity suggest that the enzyme plays a role in pulmonary disorders as well.

30 Cathepsin L is implicated in normal lysosomal proteolysis as well as several disease states, including, but not limited to, metastasis of melanomas. Cathepsin S is implicated in Alzheimer's disease and certain autoimmune disorders, including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease,

myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis and Hashimoto's thyroiditis; allergic disorders, including, but not limited to asthma; and allogeneic immune responses, including, but not limited to, rejection of organ transplants or tissue grafts.

In view of the number of diseases wherein it is recognized that an increase in cysteine protease activity contributes to the pathology and/or symptomatology of the disease, molecules which are shown to inhibit the activity of this class of enzymes, in particular molecules which are inhibitors of cathepsins B, K, L and/or S, will be useful as therapeutic agents.

10 SUMMARY OF THE INVENTION

An aspect of this invention is A compound which is selected from a group consisting of:

- 15 *N*-(1*S*-Cyanomethylcarbamoyl-2-methylbutyl)-
4-(2-pyrid-3-ylthiazol-4-yl)benzamide;
- N*-(1*S*-Cyanomethylcarbamoyl-3-methylbut-3-enyl)-
4-(2-pyrid-3-ylthiazol-4-yl)benzamide;
- N*-(1-Cyanomethylcarbamoylcyclohexyl)-
20 4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;
- N*-[1-(4-cyanotetrahydropyran-4-ylcarbamoyl)cyclohexyl]-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;
- N*-(1-cyanomethylcarbamoylcyclohexyl)-
4-(2-morpholin-4-ylthiazol-4-yl)benzamide;
- 25 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[2-(1-methylpyrid-3-yl)thiazol-4-yl]benzamide;
- 4-[2-(1-carbamoylmethylpyridin-3-yl)thiazol-4-yl]-*N*-(1*S*-cyanomethylcarbamoyl-
3-methylbutyl)benzamide;
- N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
30 4-[2-(1-methylpyridin-4-ylamino)thiazol-4-yl]benzamide;
- N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-[2-(1-methylpyridin-4-yl)thiazol-4-yl]benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-[2-(1-allylpyrid-4-yl)thiazol-4-yl]benzamide;

ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-

5 3-methylbutylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate;

ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-

3-methylbutylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(4-pyrid-4-ylthiazol-2-ylamino)benzamide;

10 *tert*-butyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl)phenyl]thiazol-2-yl}piperazine-1-carboxylate;

tert-butyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-

3-methylbutylcarbamoyl)phoxymethyl]thiazol-2-yl}piperazine-1-carboxylate;

tert-butyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-

15 3-methylbutylcarbamoyl)piperidin-1-ylmethyl]thiazol-2-yl}piperazine-1-carboxylate;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(4-morpholin-4-ylmethylthiazol-2-ylamino)benzamide;

tert-butyl 4-{2-[4-(1*S*-cyanomethylcarbamoyl)-

3-methylbutylcarbamoyl]phenylamino]thiazol-4-ylmethyl}piperazine-1-carboxylate;

20 *tert*-butyl 4-(4-{4-[1*S*-(1-cyanocyclopropylcarbamoyl)-

3-methylbutylcarbamoyl)phenyl]thiazol-2-yl}piperazine-1-carboxylate;

tert-butyl 4-(4-{4-[1*S*-(*N*-cyanomethyl-*N*-methylcarbamoyl)-

3-methylbutylcarbamoyl)phenyl]thiazol-2-yl}piperazine-1-carboxylate;

N-[1*S*-(*N*-cyanomethyl-*N*-methylcarbamoyl)-3-methylbutyl]-

25 4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;

tert-butyl 4-(4-{4-[1*S*-(1-cyanocyclopropylcarbamoyl)-

3-methylbutylcarbamoyl)phenyl]thiazol-2-ylmethyl}piperazine-1-carboxylate;

tert-butyl

4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-yl}piperazine-

30 1-carboxylate;

tert-butyl

4-(4-{4-[1-cyanomethylcarbamoyl]cyclohexylcarbamoyl}phenyl)thiazol-2-ylmethyl)piperazine-1-carboxylate;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide;

5 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperazin-1-ylthiazol-4-yl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperazin-1-ylthiazol-4-ylmethoxy)benzamide;

10 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
1-(2-piperazin-1-ylthiazol-4-ylmethyl)piperidine-4-carboxamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(4-piperazin-1-ylmethylthiazol-2-ylamino)benzamide;

N-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-
4-(2-piperazin-1-ylthiazol-4-yl)benzamide;

15 *N*!-[1*S*-(*N*-cyanomethyl-*N*-methylcarbamoyl)-3-methylbutyl]-
4-(2-piperazin-1-ylthiazol-4-yl)benzamide;

N-(1-cyanomethylcarbamoylcyclohexyl)-4-(2-piperazin-1-ylthiazol-4-yl)benzamide

;

N-(1-cyanomethylcarbamoylcyclohexyl)-
20 4-(2-piperazin-1-ylmethylthiazol-4-yl)benzamide;

ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl}thiazol-2-yl}piperazine-1-carboxylate;

N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-benzylpiperazine-1-carboxamide;

25 3-[3-(1-benzylpyrrolidin-3-yl)-3-methylureido]-*N*-(1*S*-cyanomethylcarbamoyl)-
3-methylbutyl)benzamide;

N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-(2-morpholin-4-ylethyl)piperazine-1-carboxamide;

N-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
30 4-(2-morpholin-4-ylethyl)piperazine-1-carboxamide;

4-[3-(1-benzylpiperidin-4-yl)ureido]-*N*-(1*S*-cyanomethylcarbamoyl-

3-methylbutyl)benzamide;

4-[3-(1-benzylpyrrolidin-3*S*-yl)-3-methylureido]-*N*-(1*S*-cyanomethylcarbamoyl-

3-methylbutyl)benzamide;

4-[3-(1-benzylpyrrolidin-3*R*-yl)-3-methylureido]-*N*-(1*S*-cyanomethylcarbamoyl-

5 3-methylbutyl)benzamide;

N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-

4-pyrimidin-2-ylpiperazine-1-carboxamide;

N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-oxo-

2-pyrrolidin-1-ylethyl)piperazine-1-carboxamide;

10 *N*-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-

4-pyrimidin-2-ylpiperazine-1-carboxamide;

N-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-oxo-

2-pyrrolidin-1-ylethyl)piperazine-1-carboxamide;

N-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-

15 4-benzylpiperazine-1-carboxamide;

3-[3-(1-benzylpiperidin-4-yl)ureido]-*N*-(1*S*-cyanomethylcarbamoyl-

3-methylbutyl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(2-pyrid-4-ylamino)thiazol-4-ylbenzamide;

20 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(2-pyrid-4-ylthiazol-4-yl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(2-pyrid-2-ylamino)thiazol-4-ylbenzamide;

N-{4-[4-(1*S*-cyanomethylcarbamoyl-

25 3-methylbutylcarbamoyl)phenyl]thiazol-2-yl}isonicotinamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(4-pyrid-4-ylpiperazin-1-yl)benzamide;

30 *N*-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-

4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;

- N*-(1*R*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-morpholin-4-ylthiazol-4-yl)benzamide;
4-(2-pyrid-3-ylthiazol-4-yl)benzyl 1*S*-cyanomethylcarbamoyl-
3-methylbutylcarbamate;
- 5 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;
N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-4-[*N*-methyl-
N-(4-pyrid-4-ylthiazol-2-yl)amino]benzamide;
tert-butyl
- 10 4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenoxy-methyl]thiazol-2-yl}piper-
azine-1-carboxylate;
tert-butyl 4-(4-{4-[1*S*-(1-cyanocyclopropylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl}thiazol-2-ylamino)piperidine-1-carboxylate;
N-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-
15 4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide;
tert-butyl
4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-ylamino}piperidi-
ne-1-carboxylate;
N-[1-(Cyanomethyl-carbamoyl)-2-methyl-butyl]-4-[2-(pyridin-3-ylamino)-thiazol-
20 4-yl]-benzamide;
N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[2-(piperidin-4-ylamino)-
thiazol-4-yl]-benzamide;
4-(4-{4-[1-(Cyanomethyl-carbamoyl)-
cyclohexylcarbamoyl]phenyl}-thiazol-2-ylamino)-piperidine-1-carboxylic acid ethyl ester;
25 (S)-4-Methyl-2-[4-(4-morpholin-4-yl-phenyl)-thiazol-2-ylamino]-pentanoic acid
cyanomethyl-amide;
(S)-4-Methyl-2-[4-(4-pyrrolidin-1-yl-phenyl)-thiazol-2-ylamino]-pentanoic acid
cyanomethyl-amide;
(S)-4-Methyl-2-[4-(3-phenylsulfonylureidophenyl)thiazol-2-ylamino]-pentanoic
30 acid cyanomethyl-amide;
(S)-4-Methyl-2-{4-[3-(3-phenyl-ureido)-phenyl]-thiazol-2-ylamino}-pentanoic acid

cyanomethyl-amide;

(S)-4-Methyl-2-(4-{3-[3-(4-phenoxy-phenyl)-ureido]-phenyl}-thiazol-2-ylamino)-pentanoic acid cyanomethyl-amide;

(S)-4-Methyl-2-(4-{3-[3-((R)-1-phenyl-ethyl)-ureido]-phenyl}-thiazol-2-ylamino)-pentanoic acid cyanomethyl-amide;

N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-(2-pyridin-4-yl-thiazol-4-yl)-benzamide;

(3-{2-[(S)-1-(Cyanomethyl-carbamoyl)-3-methyl-butylamino]-thiazol-4-yl}-phenyl)-carbamic acid 3,4-dichloro-benzyl ester;

N-[(S)-1-(1-Cyano-cyclopropylcarbamoyl)-3-methyl-butyl]-4-(2-piperazin-1-ylmethyl-thiazol-4-yl)-benzamide;

N-[(S)-1-(Cyanomethyl-carbamoyl)-3-methyl-but-3-enyl]-4-[2-(pyridin-4-ylamino)-thiazol-4-yl]-benzamide;

N-[(S)-1-(Cyanomethyl-carbamoyl)-2-naphthalen-2-yl-ethyl]-4-[2-(pyridin-4-ylamino)-thiazol-5-yl]-benzamide;

N-[(S)-1-(Cyanomethyl-carbamoyl)-2-naphthalen-2-yl-ethyl]-4-[2-(pyridin-4-ylamino)-thiazol-4-yl]-benzamide; and

N-[(Cyanomethyl-carbamoyl)-dimethylamino-ethyl]-4-(2-pyridin-4-yl-thiazol-4-yl)-benzamide; and the *N*-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.

A second aspect of the invention is a pharmaceutical composition which contains a compound of the invention or a *N*-oxide derivative, prodrug derivative, individual isomer or mixture of isomers or a pharmaceutically acceptable salt thereof in admixture with one or more suitable excipients.

A third aspect of the invention is a method of treating a disease in an animal in which inhibition of a cysteine protease can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of the invention or a *N*-oxide derivative, prodrug derivative, individual isomer or mixture of isomers or a pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

Definitions:


Unless otherwise stated, the following terms used in the specification and claims
 5 are defined for the purposes of this Application and have the meanings given this Section:

"Alicyclic" means a moiety characterized by arrangement of the carbon atoms in closed non-aromatic ring structures having properties resembling those of aliphatics and may be saturated or partially unsaturated with two or more double or triple bonds.

10 "Aliphatic" means a moiety characterized by straight or branched chain arrangement of the constituent carbon atoms and may be saturated or partially unsaturated with two or more double or triple bonds.

"Alkyl" indicated alone means a straight or branched, saturated or unsaturated aliphatic radical having the number of carbon atoms indicated (e.g., (C₁₋₆)alkyl includes
 15 methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, isobutyl, *tert*-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like). Alkyl indicated as part of a larger radical (e.g., as in arylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when 0 atoms are indicated means a bond (e.g.,
 20 (C₀₋₃)alkyl of (C₃₋₁₂)cycloalkyl(C₀₋₃)alkyl means a bond, methylene, ethylene, trimethylene, 1-methylethylene, or the like).

"Alkylene", unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical having the number of carbon atoms indicated (e.g. (C₁₋₆)alkylene includes methylene (-CH₂-), ethylene (-CH₂CH₂-), trimethylene
 25 (-CH₂CH₂CH₂-), 2-methyltrimethylene (-CH₂CH(CH₃)CH₂-), tetramethylene (-CH₂CH₂CH₂CH₂-), 2-butenylene (-CH₂CH=CHCH₂-), 2-methyltetramethylene (-CH₂CH(CH₃)CH₂CH₂-), pentamethylene (-CH₂CH₂CH₂CH₂CH₂-) and the like). For example, the instance wherein R⁵ is hydrogen and R⁹ taken together with R⁷ forms
 30 optionally substituted trimethylene is illustrated by the following:



in which R is an optional hydroxy or oxo group and X¹ and R¹¹ are as defined in the Summary of the Invention.

5 "Alkylidene" means a straight or branched saturated or unsaturated, aliphatic, divalent radical having the number of carbon atoms indicated (e.g. (C₁₋₆)alkylidene includes methylene (=CH₂), ethylidene (=CHCH₃), isopropylidene (=C(CH₃)₂), propylidene (=CHCH₂CH₃), allylidene (=CHCH=CH₂), and the like).

10 "Amino" means the radical -NH₂. Unless indicated otherwise, the compounds of the invention containing amino moieties include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, *tert*-butoxycarbonyl, benzyloxycarbonyl, and the like.

"Animal" includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, etc.) and non-mammals (e.g., birds, etc.).

15 "Aryl" means a monocyclic or bicyclic ring assembly (fused or linked by a single bond) containing the total number of ring carbon atoms indicated, wherein each ring is comprised of 6 ring carbon atoms and is aromatic or when fused with a second ring forms an aromatic ring assembly. For example, (C₆₋₁₂)aryl includes phenyl, naphthyl and biphenyl.

20 "Aromatic" means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp² hybridized and the total number of pi electrons is equal to 4n + 2.


"Carbamoyl" means the radical -C(O)NH₂. Unless indicated otherwise, the compounds of the invention containing carbamoyl moieties include protected derivatives thereof. Suitable protecting groups for carbamoyl moieties include acetyl, *tert*-butoxycarbonyl, benzyloxycarbonyl, and the like and both the unprotected and protected derivatives fall within the scope of the invention.

"Carboxy" means the radical -C(O)OH. Unless indicated otherwise, the compounds of the invention containing carboxy moieties include protected derivatives

thereof. Suitable protecting groups for carboxy moieties include benzyl, *tert*-butyl, and the like.

"Cycloalkyl" means a saturated or partially unsaturated, monocyclic ring, bicyclic ring assembly (directly linked by a single bond or fused) or bridged polycyclic ring assembly containing the number of annular carbon atoms indicated, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g., (C₃₋₁₂)cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclohexyl, cyclopentylcyclohexyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthalenyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-1-yl, etc.).

"Cycloalkylene" means a saturated or partially unsaturated, monocyclic ring or bridged polycyclic ring assembly containing the number of annular carbon atoms indicated, and any carbocyclic ketone, thioketone or iminoketone derivative thereof. For example, the instance wherein R⁹ and R⁵ together with the carbon atom to which both R⁹ and R⁵ are attached form (C₃₋₈)cycloalkylene" includes, but is not limited to, the following:



in which X¹ and R⁷ are as defined in the Summary of the Invention.

"Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition which may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the "side effects" of such therapy.

"Guanidino" means the radical -NHC(NH)NH₂. Unless indicated otherwise, the compounds of the invention containing guanidino moieties include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, *tert*-butoxycarbonyl, benzyloxycarbonyl, and the like.

"Halo" means fluoro, chloro, bromo or iodo.

"Halo-substituted alkyl", as a group or part of a group, means "alkyl" substituted by one or more "halo" atoms, as such terms are defined in this Application. Halo-substituted

alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g. halo-substituted (C₁₋₃)alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1-dichloroethyl, and the like).


5 "Heteroaryl" means aryl, as defined in this Application, provided that one or more of the ring member carbon atoms indicated, is replaced by heteroatom moiety selected from -N=, -NR-, -O- or -S-, wherein R is hydrogen, (C₁₋₆)alkyl or a protecting group, and each ring contained therein is comprised of 5 to 6 ring member atoms. For example, hetero(C₅₋₁₂)aryl as used in this Application includes benzofuryl, benzooxazolyl, 10 benzothiazolyl, [2,4']bipyridinyl, carbazolyl, carbolinyl, chromenyl, cinnolyl, furazanyl, furyl, imidazolyl, indazolyl, indolyl, indoliziny, isobenzofuryl, isochromenyl, isooxazolyl, isoquinolyl, isothiazolyl, naphthyridinyl, oxazolyl, perimidinyl, 2-phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyradazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolizinyl, pyrrolidinyl, pyrrolyl, pyranyl, quinazolinyl, 15 quinolizinyl, quinolyl, quinoxalinyl, tetrazolyl, thiazolyl, 4-thiazol-4-ylphenyl, thienyl, xanthenyl, and the like. Suitable protecting groups include *tert*-butoxycarbonyl, benzyloxycarbonyl, benzyl, 4-methoxybenzyl, 2-nitrobenzyl, and the like.

"Heterocycloalkyl" means cycloalkyl, as defined herein, provided that one or more of the ring member carbon atoms indicated is replaced by heteroatom moiety selected from 20 -N=, -NR-, -O-, -S- or -S(O)₂, wherein R is hydrogen, (C₁₋₆)alkyl or a protecting group, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g. the term heterocyclo(C₅₋₁₂)alkyl includes [1,4']bipiperidinyl, dihydrooxazolyl, morpholinyl, 1-morpholin-4-ylpiperidinyl, piperazinyl, piperidyl, pirazolidinyl, pirazolinyl, pyrrolinyl, pyrrolidinyl, quinuclidinyl, and the like). Suitable protecting groups include 25 *tert*-butoxycarbonyl, benzyloxycarbonyl, benzyl, 4-methoxybenzyl, 2-nitrobenzyl, and the like. For example, a compound of the Invention wherein R¹ is piperidin-4-ylcarbonyl may exist as either the unprotected or a protected derivative, e.g. wherein R¹ is 1-*tert*-butoxycarbonylpiperidin-4-ylcarbonyl, and both the unprotected and protected derivatives fall within the scope of the invention.

30 "Heterocycloalkylene" means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms indicated, is replaced by

heteroatom moiety selected from $-N=$, $-NR-$, $-O-$, $-S-$ or $-S(O)_2-$, wherein R is hydrogen or (C_{1-6}) alkyl. For example, the instance wherein R^3 and R^4 together with the carbon atom to which both R^3 and R^4 are attached form hetero(C_{3-8})cycloalkylene" includes, but is not limited to, the following:

5



in which R is hydrogen, (C_{1-6}) alkyl or a protecting group and R^2 is as defined in the Summary of the Invention.

10

"Heteropolycycloaryl" means polycycloaryl, as defined herein, except one or more of the annular carbon atoms indicated are replaced by a heteroatom moiety selected from $-N=$, $-NR-$, $-O-$, $-S-$ or $-S(O)_2-$, wherein R is hydrogen, (C_{1-6}) alkyl or a protecting group, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g., hetero(C_{8-12})polycycloaryl includes 3,4-dihydro-2H-quinolinyl,

15

5,6,7,8-tetrahydroquinolinyl, 3,4-dihydro-2H-[1,8]naphthyridinyl, morpholinylpyridyl, piperidinylphenyl, 1,2,3,4,5,6-hexahydro-[2,2']bipyridinyl, 2,4-dioxo-3,4-dihydro-2H-quinazolinyl, 3-oxo-2,3-dihydrobenzo[1,4]oxazinyl, etc.).

"Heteroatom moiety" includes $-N=$, $-NR-$, $-O-$, $-S-$ or $-S(O)_2-$, wherein R is hydrogen, (C_{1-6}) alkyl or a protecting group.

20

"Hydroxy" means the radical $-OH$. Unless indicated otherwise, the compounds of the invention containing hydroxy radicals include protected derivatives thereof. Suitable protecting groups for hydroxy moieties include benzyl and the like.

"Iminoketone derivative" means a derivative containing the moiety $-C(NR)-$, wherein R is hydrogen or (C_{1-6}) alkyl.


25

"Isomers" mean compounds of the Invention having identical molecular formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed

"diastereomers" and stereoisomers that are nonsuperimposable mirror images are termed "enantiomers" or sometimes "optical isomers". A carbon atom bonded to four nonidentical substituents is termed a "chiral center". A compound with one chiral center has two enantiomeric forms of opposite chirality is termed a "racemic mixture". A compound that has more than one chiral center has 2^{n-1} enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as either an individual diastereomers or as a mixture of diastereomers, termed a "diastereomeric mixture". When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the *R*- and *S*-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see "Advanced Organic Chemistry", 3rd edition, March, Jerry, John Wiley & Sons, New York, 1985). It is understood that the names and illustration used in this Application to describe compounds of the Invention are meant to be encompassed all possible stereoisomers. Thus, for example, the name 1-(1-cyano-1-methylethylcarbamoyl)-3-methylbutylcarbamate is meant to include 1*S*-(1-cyano-1-methylethylcarbamoyl)-3-methylbutylcarbamate and 1*R*-(1-cyano-1-methylethylcarbamoyl)-3-methylbutylcarbamate and any mixture, racemic or otherwise, thereof.

"Ketone derivative" means a derivative containing the moiety -C(O)- .

"Methylene" means the divalent radical $\text{-CH}_2\text{-}$ or $\text{CH}_2=$, wherein its free valances can be attached to different atoms or the same atom. For example, the instance wherein R^9 together with R^7 forms trimethylene substituted methylene includes the following:



in which X^1 and R^{11} are as defined in the Summary of the invention, and may be referred to as 2,2-methylene and 1,2-methylene, respectively.

"Nitro" means the radical -NO_2 .

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, the phrase "any 1 to 3 annular atoms of any aromatic ring with available valences comprising R⁶ optionally independently is substituted" means that the aromatic ring referred to may or
5 may not be substituted in order to fall within the scope of the invention.

"N-oxide derivatives" means a derivatives of compound of the Invention in which nitrogens are in an oxidized state (i.e., O-N) and which possess the desired pharmacological activity.

0 "Oxo" means the radical =O.

"Pathology" of a disease means the essential nature, causes and development of the disease as well as the structural and functional changes that result from the disease processes.


"Pharmaceutically acceptable" means that which is useful in preparing a
5 pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.

"Pharmaceutically acceptable salts" means salts of compounds of the Invention which are pharmaceutically acceptable, as defined above, and which possess the desired
0 pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartatic acid, citric acid,
5 benzoic acid, *o*-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, *p*-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, *p*-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid,
0 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic

acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.

Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, ammonium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, *N*-methylglucamine and the like.

"Phenylene-1,2-dimethylene" means the divalent radical $-\text{CH}_2\text{C}_6\text{H}_4\text{CH}_2-$, wherein the methylene moieties are attached at the 1- and 2-positions of the phenylene moiety. For example, a group of Formula (a), wherein R^9 together with R^7 form optionally substituted phenylene-1,2-dimethylene is illustrated by the following formula:



in which R is an optional hydroxy or (C_{1-4}) alkyl group and X^1 and R^{11} are as defined in the Summary of the Invention.

"Polycycloaryl" means a bicyclic ring assembly (directly linked by a single bond or fused) containing the number of ring member carbon atoms indicated, wherein at least one, but not all, of the fused rings comprising the radical is aromatic, and any carbocyclic ketone, thioketone or iminoketone derivative thereof (e.g., (C_{9-12}) polycycloaryl includes indanyl, indenyl, 1,2,3,4-tetrahydronaphthalenyl, 1,2-dihydronaphthalenyl, cyclohexylphenyl, phenylcyclohexyl, 2,4-dioxo-1,2,3,4-tetrahydronaphthalenyl, and the like).

"Prodrug derivatives" means derivatives of compounds of the Invention which are converted *in vivo* to the corresponding non-derivatized form of a compound of the Invention.

"Protected derivatives" means derivatives of compounds of the Invention in which a reactive site or sites are blocked with protecting groups. Protected derivatives of

compounds of the Invention are useful in the preparation of compounds of Formula I or in themselves may be active cysteine protease inhibitors. A comprehensive list of suitable protecting groups can be found in T.W. Greene, *Protecting Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1981.

5 "Therapeutically effective amount" means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

"Thioketone derivative" means a derivative containing the moiety $-C(S)-$.

"Treatment" or "treating" means any administration of a compound of the present invention and includes:

10 (1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease,

(2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or

15 (3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).

"Ureido" means the radical $-NHC(O)NH_2$. Unless indicated otherwise, the compounds of the invention containing ureido moieties include protected derivatives thereof. Suitable protecting groups for ureido moieties include acetyl, *tert*-butoxycarbonyl, benzyloxycarbonyl, and the like.

Pharmacology and Utility:

25 The compounds of the invention are cysteine protease inhibitors, in particular the compounds of the invention inhibit the activity of cathepsins B, L, K and/or S and, as such, are useful for treating diseases in which cathepsin B, L, K and/or S activity contributes to the pathology and/or symptomatology of the disease. For example, the compounds of the invention are useful in treating tumor invasion and metastasis, in particular as


30 anti-angiogenic agents, rheumatoid arthritis, osteo arthritis, pneumocystis carinii, acute pancreatitis, inflammatory airway disease and bone and joint disorders. Furthermore, the

compounds of the invention are useful in treating bone resorption disorders, e.g., osteoporosis. The compounds of the invention also are useful in treating autoimmune disorders, including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis and Hashimoto's thyroiditis, allergic disorders, including, but not limited to asthma, and allogeneic immune responses, including, but not limited to, organ transplants or tissue grafts.

The cysteine protease inhibitory activities of the compounds of the invention can be determined by methods known to those of ordinary skill in the art. Suitable *in vitro* assays for measuring protease activity and the inhibition thereof by test compounds are known. Typically, the assay measures protease induced hydrolysis of a peptide based substrate.

Nomenclature:

The compounds of the Invention and the intermediates and starting materials used in their preparation The compounds of the invention and the intermediates and starting materials used in their preparation are named in accordance with IUPAC rules of nomenclature in which the characteristic groups have decreasing priority for citation as the principle group as follows: acids, esters, amides, etc.. Alternatively, the compounds are named by AutoNom 4.0 (Beilstein Information Systems, Inc.). For example, a compound of the Invention in which R¹ is 4-(2-meth-4-ylthiazolyl)benzoylaminobutyryl and R², R³ and R⁴ are each hydrogen; that is, a compound having the following structure:



is named ethyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]phenyl]thiazol-2-ylamino}piperidine-1-carboxylate or

4-(4-{4-[(*S*)-1-(cyanomethyl-carbamoyl)-3-methyl-butylcarbamoyl]-phenyl}-thiazol-2-ylamino)-piperidine-1-carboxylic acid ethyl ester.

Administration and Pharmaceutical Compositions:

5 In general, compounds of the Invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with another therapeutic agent. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. For example, therapeutically
10 effective amounts of a compound of the Invention may range from 0.1 micrograms per kilogram body weight ($\mu\text{g/kg}$) per day to 10 milligram per kilogram body weight (mg/kg) per day, typically 1 $\mu\text{g/kg/day}$ to 1 mg/kg/day . Therefore, a therapeutically effective amount for a 80 kg human patient may range from 10 $\mu\text{g/day}$ to 100 mg/day , typically 0.1 mg/day to 10 mg/day . In general, one of ordinary skill in the art, acting in reliance
15 upon personal knowledge and the disclosure of this Application, will be able to ascertain a therapeutically effective amount of a compound of the Invention for treating a given disease.


 The compounds of the Invention can be administered as pharmaceutical compositions by one of the following routes: oral, systemic (e.g., transdermal, intranasal or
20 by suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate composition and are comprised of, in general, a compound of the Invention in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are
25 non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the active ingredient. Such excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

 Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate,
30 glycerol monostearate, sodium chloride, dried skim milk, and the like. Liquid and semisolid excipients may be selected from water, ethanol, glycerol, propylene glycol and

various oils, including those of petroleum, animal, vegetable or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.). Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose and glycols.

The amount of a compound of the Invention in the composition may vary widely depending upon the type of formulation, size of a unit dosage, kind of excipients and other factors known to those of skill in the art of pharmaceutical sciences. In general, a composition of a compound of the Invention for treating a given disease will comprise from 0.01%w to 10%w, preferably 0.3%w to 1%w, of active ingredient with the remainder being the excipient or excipients. Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. Representative pharmaceutical formulations containing a compound of the Invention are described in Example 17.

The compounds of the Invention can be administered alone or in combination with other compounds of the Invention or in combination with one or more other active ingredient(s). For example, the compounds of the Invention can be administered in combination with a therapeutically active amount of a bisphosphonic acid or acid ester derivative or any pharmaceutically acceptable salt thereof. Suitable bisphosphonic acids and acid ester derivatives include compounds corresponding to the following formula:



wherein X^{11} is a bond or (C_{1-7}) alkylene, each R^{43} independently is hydrogen or (C_{1-30}) alkyl, R^{44} and R^{45} are selected independently from a group consisting of hydrogen, halo, optionally substituted (C_{1-30}) alkyl, (C_{3-30}) cycloalkyl, hetero (C_{3-30}) cycloalkyl, optionally substituted (C_{6-10}) aryl, hetero (C_{6-10}) aryl, $-\text{NR}^{46}\text{R}^{46}$, $-\text{OR}^{46}$, $-\text{SR}^{46}$, wherein each R^{46} independently is hydrogen, (C_{1-10}) alkyl, (C_{3-10}) cycloalkyl, optionally substituted (C_{6-10}) aryl, provided that both R^{44} and R^{45} are not selected from hydrogen or hydroxy when X^{11} is a bond; or R^{44} and R^{45} taken together form (C_{2-9}) alkylene; wherein (C_{3-10}) cycloalkyl includes adamantyl and the like, hetero (C_{5-10}) cycloalkyl includes pyrrolidinyl and the like,

(C₆₋₁₀)aryl includes phenyl and naphthyl, and hetero(C₆₋₁₀)aryl includes quinolyl, isoquinolyl, pyridyl, furyl, imidazolyl, imidazopyridyl and the like.

Instances wherein R⁴⁴ and/or R⁴⁵ are substituted (C₁₋₃₀)alkyl may include, but are not limited to, (C₁₋₃₀)alkyl substituted by hetero(C₅₋₁₀)cycloalkyl, (C₆₋₁₀)aryl, hetero(C₆₋₁₀)aryl, -NR⁴⁷R⁴⁷, -OR⁴⁷ and -SR⁴⁷, wherein each R⁴⁷ is independently hydrogen or (C₁₋₁₀)alkyl; wherein hetero(C₅₋₁₀)cycloalkyl includes pyrrolidinyl and the like, (C₆₋₁₀)aryl includes phenyl and naphthyl, and hetero(C₆₋₁₀)aryl includes quinolyl, isoquinolyl, pyridyl, furyl, imidazolyl, imidazopyridyl and the like. Suitable optionally substituted aryl groups include, but are not limited to, halo-substituted phenyl.

A non-limiting class of bisphosphonic acids and acid ester derivatives thereof suitable for administration in combination with compounds of the Invention include those in which R⁴⁴ is selected from the group consisting of hydrogen, hydroxy or halo, and R⁴⁵ is selected from the group consisting of optionally substituted (C₁₋₃₀)alkyl, halo and -SR⁴⁶, wherein R⁴⁶ is (C₁₋₁₀)alkyl or phenyl.

A non-limiting subclass of bisphosphonic acids and acid ester derivatives thereof suitable for administration in combination with compounds of the Invention include those in which R⁴⁴ is selected from the group consisting of hydrogen, hydroxy and chloro and R⁴⁵ is selected from the group consisting of optionally substituted (C₁₋₃₀)alkyl, chloro and chlorophenylthio.

A non-limiting example of a bisphosphonic acid suitable for administration in combination with compounds of the Invention include that in which X¹¹ is a bond, each R⁴³ is hydrogen, R⁴⁴ is hydroxy and R⁴⁵ is 3-aminopropyl, namely 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (aka alendronic acid), or the monosodium trihydrate salt thereof, namely 4-amino-1-hydroxybutylidene-1,1-bisphosphonate monosodium trihydrate (aka alendronate monosodium trihydrate), described in U.S. Patents 4,922,007, to Kieczkowski et al., issued May 1, 1990; 5,019,651, to Kieczkowski et al., issued May 28, 1991; 5,510,517, to Dauer et al., issued April 23, 1996; 5,648,491, to Dauer et al., issued July 15, 1997, all of which patents are incorporated by reference herein in their entirety.

Further non-limiting examples of bisphosphonic acids suitable for administration in combination with compounds of the Invention include the following:

cycloheptylaminomethylene-1,1-bisphosphonic acid (aka cimadronic acid), described in U.S. Patent 4,970,335, to Isomura et al., issued November 13, 1990;

1,1-dichloromethylene-1,1-diphosphonic acid (aka clodronic acid) and the disodium salt thereof, namely clodronate disodium, described in Belgium Patent 672,205 (1966) and *J. Org. Chem* 32, 4111 (1967);

1-hydroxy-3-pyrrolidin-1-ylpropylidene-1,1-bisphosphonic acid (aka EB-1053);

1-hydroxyethylidene-1,1-diphosphonic acid (aka etidronic acid);

1-hydroxy-3-(*N*-methyl-*N*-pentylamino)propylidene-1,1-bisphosphonic acid (aka ibandronic acid), described in U.S. Patent No. 4,927,814, issued May 22, 1990;

6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (aka neridronic acid);

3-(dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid (aka olpadronic acid);

3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid (aka pamidronic acid);

2-pyrid-2-ylethylidene-1,1-bisphosphonic acid (aka piridronic acid), described in U.S. Patent No. 4,761,406;

1-hydroxy-2-pyrid-3-ylethylidene-1,1-bisphosphonic acid (aka risedronic acid);

4-chlorophenylthiomethylenebisphosphonic acid (aka tiludronic acid), described in U.S. Patent 4,876,248, to Breliere et al., October 24, 1989; and

1-hydroxy-2-(1*H*-imidazol-1-yl)ethylidene-1,1-bisphosphonic acid (aka zoledronic acid); all of which patents and other documents referred to above are incorporated by reference herein in their entirety.

A non-limiting subclass of bisphosphonic acids suitable for administration in combination with compounds of the Invention include those selected from the group consisting of alendronic acid, cimadronic acid, clodronic acid, tiludronic acid, etidronic acid, ibandronic acid, risedronic acid, piridronic acid, pamidronic acid, zolendronic acid, pharmaceutically acceptable salts thereof, and mixtures thereof. A further example of a bisphosphonic acid suitable for administration in combination with compounds of the Invention is alendronic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof. A further non-limiting example is alendronate monosodium trihydrate.

Compounds of the Invention can be administered in combination with a therapeutically active amount of an estrogen receptor agonist. Non-limiting examples of

estrogen receptor agonists suitable for administration in combination with the compounds of the Invention include naturally occurring estrogens such as estradiol, estrone and estroil, or synthetic estrogen receptor agonists such as

[6-hydroxy-2-(4-hydroxyphenyl)benzo[*b*]thien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone

(aka raloxifene) and {2-[4-(1,2-diphenylbut-1-enyl)phenoxy]ethyl}dimethylamine (aka tamoxifen). A non-limiting subclass of estrogen receptor agonists suitable for

administration in combination with the compounds of the Invention include estrogen receptor partial agonists (i.e., estrogen receptor agonists with mixed agonist/antagonist properties), sometimes referred to as estrogen receptor modulators. Estrogen receptor partial agonists can exert tissue-selective estrogen agonist effects. Tamoxifen, for example, selectively exerts an estrogen agonist effect on the bone, in humans. Additional suitable estrogen receptor partial agonists are described in Tissue-Selective Actions Of Estrogen Analogs, Bone Vol. 17, No. 4, October 1995, 181S-190S. Certain

3-[4-(2-phenylindol-1-ylmethyl)phenyl]acrylamides, described in U.S. Patent 5,985,910 to Miller *et al.*, November 16, 1999; benzothiphenes compounds, described in U.S. Patent 5,985,897 to Meuhl *et al.*, November 16, 1999; naphthyl compounds, described in U.S. Patent 5,952,350 to Cullinan *et al.*, September 14, 1999; substituted benzothiophene compounds, described in U.S. Patent 5,962,475 to Schmid *et al.*, October 4, 1999, are suitable estrogen receptor partial agonists for administration with the compounds of the Invention; all of which patents and other documents referred to above are incorporated by reference herein in their entirety.

More particularly a pharmaceutical composition of this invention may comprise a therapeutically effect amount of a compound of the Invention in combination with one or more active ingredient(s) selected from the group consisting of (i) a therapeutically effect amount of a bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof and (ii) a therapeutically effect amount of an estrogen receptor agonist or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable excipient(s). Non-limiting examples of such bisphosphonic acids include

1,1-dichloromethylene-1,1-diphosphonic acid, 1-hydroxy-3-pyrrolidin-1-ylpropylidene-1,1-bisphosphonic acid, 1-hydroxyethylidene-1,1-diphosphonic acid, 1-hydroxy-3-(*N*-

5 methyl-*N*-pentylamino)propylidene-1,1-bisphosphonic acid, 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid, 3-(dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid, 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid, 2-pyrid-2-ylethylidene-1,1-bisphosphonic acid, 1-hydroxy-2-pyrid-3-ylethylidene-1,1-bisphosphonic acid, 4-chlorophenylthiomethylenebisphosphonic acid and 1-hydroxy-2-(1*H*-imidazol-1-yl)ethylidene-1,1-bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof; particularly 1,1-dichloromethylene-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof and preferably 1,1-dichloromethylene-1,1-diphosphonate monosodium trihydrate.

10


Chemistry:

Processes for Making Compounds of the Invention:

Compounds of the Invention can be prepared by proceeding as in the following

5 Scheme 1:

Scheme 1



10

in which Y is hydrogen or an activating group (e.g., 2,5-dioxopyrrolidin-1-yl (NBS), and the like) and each R¹, R², R³ and R⁴ are as defined in the Summary of the Invention.

15

Compounds of the Invention can be prepared by reacting a compound of Formula 2, or a protected derivative thereof, with a compound of the formula R¹OY, or a protected derivative thereof, and then optionally deprotecting. The reaction is carried out in the presence of a suitable acylation catalyst (e.g., triethylamine) and in a suitable solvent (e.g., acetonitrile, *N,N*-dimethylformamide (DMF), methylene chloride, or any suitable combination thereof) at 10 to 30°C, preferably at about 25°C, and requires 24 to 30 hours to complete. When Y is hydrogen the reaction can be effected in the presence of a suitable coupling agent (e.g., benzotriazole-1-yloxytrispyrrolidinophosphonium

20


hexafluorophosphate (PyBOP®), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HBTU), 1,3-dicyclohexylcarbodiimide (DCC), or the like) and base (e.g., *N,N*-diisopropylethylamine, triethylamine, or the like) and requires 2 to 15 hours to complete. Alternatively, when Y is hydrogen the reaction can be carried out by treating the compound of formula R¹OH with *N*-methylmorpholine and isobutyl chloroformate in a suitable solvent (e.g., THF, or the like) at between 0 and 5°C for 30 minutes to an hour and then introducing the compound of Formula 2 to the reaction mixture and allowing the reaction to proceed for 12 to 15 hours.

Deprotection can be effected by any means which removes the protecting group and gives the desired product in reasonable yield. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, *Protecting Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1981.

Alternatively, compounds of the Invention can be prepared by reacting a compound of Formula 2 with a compound of the formula R¹-SS, wherein SS is a suitable solid support (e.g., thiophenol resin, or the like). The reaction can be carried out in the presence of a suitable acylation catalyst (e.g., 4-dimethylaminopyridine, or the like) and in a suitable solvent (e.g., dry pyrimidine, or the like) and requires 60 to 70 hours to complete.

Compounds of the Invention can be prepared by proceeding as in the following reaction Scheme 2:

Scheme 2



in which each R^1 , R^2 , R^3 and R^4 are as defined in the Summary of the Invention.

Compounds of the Invention can be prepared by treating a compound of Formula 3,
 5 or a protected derivative thereof, with ammonia to provide a corresponding amide, then
 reacting the amide with a suitable dehydrating agent (e.g., trifluoroacetic anhydride,
 cyanuric chloride, thionyl chloride, phosphonyl chloride, and the like) and optionally
 deprotecting. The reaction with the ammonia is carried out in a suitable solvent
 (e.g., methanol) at between 0 and 5°C and requires 6 to 10 days to complete. The reaction
 10 with the dehydrating agent is carried out in the presence of a suitable base (e.g.,
 triethylamine) and in a suitable solvent (e.g., tetrahydrofuran (THF), and the like) at
 between 0 and 50°C and requires 1 to 2 hours to complete.

Additional Processes for Preparing Compounds of the Invention:

15 A compound of the Invention can be prepared as a pharmaceutically acceptable acid
 addition salt by reacting the free base form of the compound with a pharmaceutically
 acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base
 addition salt of a compound of the Invention can be prepared by reacting the free acid form
 of the compound with a pharmaceutically acceptable inorganic or organic base. Inorganic
 20 and organic acids and bases suitable for the preparation of the pharmaceutically acceptable
 salts of compounds of the Invention are set forth in the definitions section of this

application. Alternatively, the salt forms of the compounds of Formula I can be prepared using salts of the starting materials or intermediates.

The free acid or free base forms of the compounds of Formula I can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound of the Invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, etc.). A compound of Formula I in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).

The *N*-oxides of compounds of the Invention can be prepared by methods known to those of ordinary skill in the art. For example, *N*-oxides can be prepared by treating an unoxidized form of the compound of the Invention with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, *meta*-chloroperoxybenzoic acid, etc.) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as methylene chloride) at approximately 0°C. Alternatively, the *N*-oxides of the compounds of the Invention can be prepared from the *N*-oxide of an appropriate starting material.

Compounds of the Invention in unoxidized form can be prepared from *N*-oxides of compounds of Formula I by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, etc.) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, etc.) at 0 to 80°C.

Prodrug derivatives of the compounds of the Invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier *et al.* (1994), *Bioorganic and Medicinal Chemistry Letters*. 4:1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of the Invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, *para*-nitrophenyl carbonate, etc.).


Protected derivatives of the compounds of the Invention can be made by means known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W.

Greene, *Protecting Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1981.

Compounds of the Invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds of the Invention, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, *Enantiomers, Racemates and Resolutions*, John Wiley & Sons, Inc. (1981).


In summary, an aspect of the invention is a process for preparing a compound of the Invention, which process comprises:

(A) reacting a compound of Formula 2:



or a protected derivative thereof with a compound of the formula R^1OY , or a protected derivative thereof, in which Y is hydrogen or an activating group and each R^1 , R^2 , R^3 and R^4 are as defined in the Summary of the Invention; or

(B) reacting a compound of Formula 3:



with ammonia to provide a corresponding amide and then reacting the amide with trifluoroacetic anhydride, in which each R^1 , R^2 , R^3 and R^4 are as defined in the Summary of the Invention

(C) optionally deprotecting a protected derivative of a compound of the Invention to provide a corresponding unprotected derivative;

(D) optionally converting a compound of the Invention into a pharmaceutically acceptable salt;

(E) optionally converting a salt form of a compound of the Invention to non-salt form;

(F) optionally converting an unoxidized form of a compound of the Invention into a pharmaceutically acceptable *N*-oxide;


(G) optionally converting an *N*-oxide form of a compound of the Invention to its unoxidized form;

(H) optionally converting a non-derivatized compound of the Invention into a pharmaceutically prodrug derivative; and

(I) optionally converting a prodrug derivative of a compound of the Invention to its non-derivatized form.

Processes for Preparing Intermediates:

Compounds of Formula 2 can be prepared by reacting a compound of Formula 4:




in which R^{19} is an amino protecting group and each R^2 , R^3 and R^4 are as defined in the Summary of the Invention, with thionyl chloride and then deprotecting. The reaction with


the thionyl chloride is carried out in the presence of a suitable base (e.g, triethylamine) and in a suitable solvent (e.g, DMF) at between 0 and 5°C and requires 30 minutes to an hour to complete. Alternatively, compounds of Formula 2 can be prepared by reacting a compound of Formula 4 with trifluoroacetic anhydride. The deprotection can be effected by any means which removes the protecting group and gives the desired product in reasonable yield. A detailed description of the preparation of a compound of Formula 2 according to above-described procedure is set forth in Example 1, *infra*.

Compounds of Formula 4 can be prepared by treating a corresponding alkanoyl halide with ammonia. The treatment is carried out in a suitable solvent (e.g., dichloromethane, 5% aqueous sodium carbonate, and the like, or any suitable combination thereof) at 10 to 30°C and requires 30 minutes to an hour to complete. The alkanoyl halide intermediates can be prepared from the corresponding alkanoyl acid by treating with thionyl chloride in a suitable solvent (e.g., dichloromethane) under nitrogen for 30 minutes to an hour. A detailed description of the preparation of a compound of Formula 2 according to the above-described procedures is set forth in Example 1, *infra*.

Compounds of the formula R¹-SS can be prepared by reacting a compound of Formula 5(a) or 5(b):




in which R¹⁹ is an amino protecting group (e.g., tert-butoxycarbonyl, fluoren-9-ylmethoxycarbonyl, or the like) and each X¹, X², X³, R⁵ and R⁷ are as defined for Formula I in the Summary of the Invention, with a suitable solid support resin (e.g, Wang (4-benzyloxybenzyl alcohol) resin, thiophenol resin, or the like), deprotecting to provide, respectively, a compound of Formula 6(a) or 6(b):



in which SS is a solid support and then reacting the compound of Formula 6(a) or 6(b) with a compound of the formula R^6OH (e.g., benzoic acid, indole-5-carboxylic acid, methanesulfonic acid, or the like).

The reaction between the compound of Formula 5(a) or 5(b) and the resin is carried out in the presence of a suitable coupling agent (e.g., benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate (e.g., diisopropylcarbodiimide (DIC), PyBOP®, EDC, HBTU, DCC, or the like) and acylation catalyst (e.g., *N,N*-diisopropylethylamine, triethylamine, 4-dimethylaminopyridine, 1-hydroxybenzotriazole hydrate, or the like) in a suitable solvent (e.g., methylene chloride, DMF, or the like) and requires approximately 3 to 20 hours to complete. Deprotection can be effected by any means which removes the protecting group and gives the desired product in reasonable yield. The reaction between the compound of Formula 6(a) or 6(b) is carried out with a suitable coupling agent and acylation catalyst. A detailed description of the preparation of a compound of the formula R^1SS according to the above-described procedures is set forth in Examples 2(A-C) and 4(A-C), *infra*.

Compounds of the formula R^1OH can be prepared by treating a compound of formula R^1SS with a suitable acid (e.g., trifluoroacetic acid, or the like) in a suitable solvent (e.g., methylene chloride, or the like). Alternatively, compounds of the formula R^1OH in which X^1 is $-\text{C}(\text{O})-$ and X^2 is $-\text{CHR}^9-$ can be prepared by alkylating an organometallic compound of Formula 7(a) or 7(b):



with a compound of the formula R^9L , in which L is a leaving group and each X^3 , X^4 , R^5 , R^6 , R^7 and R^9 are as defined for Formula I in the Summary of the Invention, and then converting the resulting ethyl ester to the corresponding acid. The alkylation is carried out in a suitable solvent (e.g., THF) at -78°C to 0°C and requires 1 to 2 hours to complete.

- 5 Conversion the acid can be effected by treating the ester with lithium hydroxide for approximately 15 hours. The organometallic compound is generated by treating a corresponding organo compound with an appropriate base (e.g., *N,N*-diisopropylethylamine, triethylamine, and the like) and *n*-butyllithium or *tert*-butyllithium at -80 to -70°C , preferably at about -78°C , for approximately 30 minutes
10 to an hour. A detailed description of the preparation of a compound of the formula $R^1\text{OH}$ according to the above-described procedures is set forth in Example 3, infra.

Examples:

15

REFERENCE 7

4-(2-Pyrid-3-ylaminothiazol-4-yl)benzoic acid

- A solution of 4-bromoacetylbenzoic acid (2.2 g, 10 mmol) in ethanol (50 mL) was
20 treated with pyrid-3-ylthiourea (1.53 g, 1 mmol) and the mixture was refluxed for 3 hr. Solids were collected by filtration, washed with ether and dried to provide
4-(2-pyrid-3-ylaminothiazol-4-yl)benzoic acid (2.2 g, 74% yield). LC-MS: FAB LC-MS. 298.2 ($M+H^+$).

25

Proceeding as in Reference 7 provided

4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzoic acid LC-MS: FAB LC-MS 304.2 ($M+H^+$).

30

REFERENCE 8

tert-Butyl 4-methyl-2*S*-[4-(2-pyrid-3-ylamino)thiazol-4-yl]benzoylaminopentanoate

A mixture of 4-(2-pyrid-3-ylaminothiazol-4-yl)benzoic acid (10 gm, 33.6 mmol),

provided as in Reference 7, *tert*-butyl 2*S*-amino-4-methylpentanoate (7.5 gm, 33.3 mmol), HBTU (13.3 gm, 33.3 mmol) and triethylamine (10.0 mL, 67.0 mmol) was stirred for approximately 12 hours and then diluted with sodium bicarbonate (50 mL) and ethyl acetate (300 mL). The organic layer was separated, sequentially washed with water and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in ethylacetate and hexane and product was recrystallized to provide *tert*-butyl 4-methyl-2*S*-[4-(2-pyrid-3-ylamino)thiazol-4-yl]benzoylaminopentanoate (10 gm, 62% yield). LC-MS: 467.1 M+H⁺.

REFERENCE 9

1-Amino-N-cyanomethylcyclohexanecarboxamide methanesulfonic acid salt

1-Benzyloxycarbonylaminocyclohexanecarboxylic acid (5.0 gm, 21.0 mmol) was taken up in DMF (40 mL). The mixture was cooled in an ice bath and then sequentially treated with aminoacetonitrile hydrochloride (3.8 gm, 42 mmol), HATU (8.25 gm, 21 mmol) and triethylamine (8.0 mL, 63 mmol). The reaction was allowed to proceed for 4 hours and then the mixture was concentrated under vacuum. The residue was treated with saturated NaHCO₃ solution (40 mL) and ethyl acetate (150 mL). The organic layer was separated, sequentially washed with water, 1 M hydrochloric acid (20 mL), water and brine and dried over anhydrous MgSO₄ and concentrated under reduced pressure. The free base of the product was purified from the residue using a plug of silica with ethyl acetate as an eluant. The free base of the product was taken up in dichlormethane (20 ml) and methanesulfonic acid (3.0 eq) and the mixture stirred for approximately 12 hours. The mixture was concentrated and the residue was triturated with ether (100 ml) and dried under vacuum to provide 1-amino-N-cyanomethylcyclohexanecarboxamide methanesulfonic acid salt (5.5 gm, 100% yield). LC-MS: 182.2, M+H⁺.

REFERENCE 10

4-[2-(4-*tert*-butoxycarbonylpiperazin-1-yl)thiazol-4-ylmethoxy]benzoic acid

A solution of *tert*-butyl 4-thiocarbamoylpiperazine-1-carboxylate (650 mg, 2.65 mmol) and 1,3-dichloroacetone (672 mg, 5.3 mmol) in 1,2-dichloroethane was treated with sodium bicarbonate (22 mg, 2.65 mmol). The reaction mixture was stirred at 70°C for 18 hours and then diluted with chloroform. The dilution was washed with water and brine, dried over sodium sulfate and concentrated. Product was purified from the residue on a silica gel column, using ethyl acetate/hexanes (3/7) as eluent, to provide *tert*-butyl 4-(4-chloromethylthiazol-2-yl)piperazine-1-carboxylate (830 mg, 100% yield). HNMR (dms_o-d₆): 6.92 (1H, s), 4.57 (2H, s), 3.40 (8H, m), 1.42 (9H, s).

A solution of *tert*-butyl 4-(4-chloromethylthiazol-2-yl)piperazine-1-carboxylate (820 mg, 2.58 mmol) and methyl 4-hydroxybenzoate (395 mg, 2.58 mmol) in DMF was treated with potassium carbonate (360 mg, 2.6 mmol). The mixture was stirred at 70°C for approximately 12 hours and then concentrated under vacuum. The residue was partitioned between ethyl acetate and water and the organic phase was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was crystallized from a mixture of ethyl acetate/hexanes to provide *tert*-butyl 4-[4-(4-methoxycarbonylphenoxy)methyl]thiazol-2-yl]piperazine-1-carboxylate (830 mg, 74% yield). HNMR (dms_o-d₆): HNMR (dms_o-d₆): 7.91 (2H, d), 7.13 (2H, d), 6.91 (1H, s), 5.00 (2H, s), 3.81 (3H, s), 3.41 (8H, m), 1.41 (9H, s).

A solution of *tert*-butyl 4-[4-(4-methoxycarbonylphenoxy)methyl]thiazol-2-yl]piperazine-1-carboxylate (820 mg, 1.89 mmol) in methanol (30 mL) and THF (10 mL) was treated with a solution of sodium hydroxide (226 mg, 5.67 mmol) in water (10 mL). The mixture was stirred at 55 °C for 8 hours and then concentrated by evaporation. The aqueous solution was diluted with water (10 mL) and the dilution was acidified with dilute hydrochloric acid. A resulting solid was collected by filtration to provide 4-[2-(4-*tert*-butoxycarbonylpiperazin-1-yl)thiazol-4-ylmethoxy]benzoic acid (800 mg, 100% yield). HNMR (dms_o-d₆): 7.88 (2H, d), 7.09 (2H, d), 6.91 (1H, s), 4.99 (2H, s), 3.44 (8H, m), 1.41 (9H, s).

Proceeding as in Reference 10 provided 4-(4-morpholin-4-ylmethylthiazol-2-ylamino)benzoic acid.

REFERENCE 11

tert-Butyl 4-[4-(4-methoxycarbonylpiperidin-1-ylmethyl)thiazol-2-yl]piperazine-1-carboxylate

5 A solution of *tert*-butyl 4-(4-chloromethylthiazol-2-yl)piperazine-1-carboxylate (860 mg, 2.7 mmol) and methyl piperidine-4-carboxylate (539 mg, 3 mmol) in DMF was treated with potassium carbonate (414 mg, 3 mmol). The mixture was stirred at 70°C for 18 hours and then concentrated under vacuum. Product was purified from the residue by
10 flash chromatography on silica gel to provide *tert*-butyl 4-[4-(4-methoxycarbonylpiperidin-1-ylmethyl)thiazol-2-yl]piperazine-1-carboxylate (575 mg, 50% yield). HNMR (dms_o-d₆): 6.58 (1H, s), 3.59 (2H, s), 3.42 (4H, m), 3.34 (4H, m), 3.32 (3H, s), 2.78 (2H, m), 2.28 (1H, m), 2.02 (2H, m), 1.77 (2H, m), 1.57 (2H, m), 1.41 (3H, s).

15 Proceeding as in Reference 11 provided the following compounds:

tert-butyl 4-[2-(4-methoxycarbonylphenylamino)thiazol-4-ylmethyl]piperazine-1-carboxylate;

HNMR (dms_o-d₆): 10.6 (1H, s), 7.90 (2H, d), 7.70 (2H, d), 6.78 (1H, s), 3.80 (3H, s), 3.51 (2H, s), 3.32 (4H, m), 2.42 (4H, m), 1.41 (9H, s); and

20 *tert*-butyl 4-cyanomethyl-piperazine-1-carboxylate; HNMR (dms_o-d₆): 3.75 (2H, s), 3.34 (4H, t), 2.41 (4H, t), 1.40 (9H, s).

REFERENCE 12

1-[2-(4-*tert*-Butoxycarbonylpiperazin-1-yl)thiazol-4-ylmethyl]piperidine-4-carboxylic acid

25 A solution of *tert*-butyl 4-[4-(4-methoxycarbonylpiperidin-1-ylmethyl)thiazol-2-yl]piperidine-1-carboxylate (560 mg, 1.31 mmol), provided as in Reference 11, in methanol (30 mL) was treated at room temperature with a solution of sodium hydroxide (79 mg, 1.97 mmol) in water (10 mL). The mixture was heated at 50°C for 3 hours and concentrated to dryness to provide
30 1-[2-(4-*tert*-butoxycarbonylpiperazin-1-yl)thiazol-4-ylmethyl]piperidine-4-carboxylic acid.

Proceeding as in Reference 12 provided the following compounds:

4-[2-(1-*tert*-butoxycarbonylpiperazin-1-yl)methylthiazol-4-ylamino]piperadinecarboxylic acid.

5

REFERENCE 13

tert-Butyl 4-thiocarbamoylmethylpiperazine-1-carboxylate

A solution of *tert*-butyl 4-cyanomethylpiperazine-1-carboxylate (4.5 g, 0.020 mol) in a 3:1 mixture of triethylamine/pyridine (40 mL) at room temperature was bubbled with hydrogen sulfide for 30 minutes. The reaction mixture was stirred for 18 hours at room temperature and then concentrated under vacuum. The residue was treated with a mixture 1:4 mixture of ethyl acetate/hexane and the resulting solid was collected by filtration and washed with the ethyl acetate/hexane mixture to provide *tert*-butyl 4-thiocarbamoylmethylpiperazine-1-carboxylate (3.93 g, 75%). HNMR (dmso-d₆): 9.87 (1H, bs), 9.07 (1H, bs), 3.35 (4H, t), 2.34 (4H, t), 1.29 (9H, s); LC/MS: M+1: 259.6.

15

REFERENCE 14

4-[2-(1-Ethoxycarbonylpiperidin-4-ylamino)thiazol-4-yl]benzoic acid

20

A solution of ethyl 4-aminopiperidine-1-carboxylate (4.3 g, 0.025 mol) in dry THF was cooled to 0°C and then treated with triethylamine (3.83 mL, 27.5 mmol) and thiophosgene (2.1 mL, 27.5 mmol). The mixture was stirred for 1.5 hours at room temperature, cooled at 0° C and then treated with ammonium hydroxide solution (7.7 mL, 28% in water). The mixture was stirred for approximately 12 hours and then concentrated by evaporation. The residue was taken up into ethyl acetate and the mixture was treated with a saturated solution of NaHCO₃ and brine. The organic phase was separated, dried over sodium sulfate and then concentrated to dryness. The residue was taken up into diethyl ether and a resulting solid was collected by filtration and washed with diethyl ether to provide ethyl 4-thioureidopiperidine-1-carboxylate (4.18 g, 72 % V). HNMR (dmso-d₆): 7.57 (1H, d), 6.9 (1H, s), 4.05 (1H, bs), 4.02 (2H, q), 3.86 (2H, d), 2.89 (2H, bs), 1.82 (2H, bs), 1.20 (2H, m), 1.17 (3H, t).

30

A solution of ethyl 4-thioureidopiperidine-1-carboxylate (3.8 g, 0.0164 mol.) and

4-(2-bromoacetyl)benzoic acid (4 g, 0.0164 mmol) in THF (100 mL) was heated at 70° C for 2 hours, cooled to room temperature and then diluted with diethyl ether. A resulting solid was collected by filtration and washed with diethyl ether to provide 4-[2-(1-ethoxycarbonylpiperidin-4-ylamino)thiazol-4-yl]benzoic acid (4.32 g, 70% yield) as an off white solid. HNMR (dmso-d6): 7.93 (4H, m), 7.27 (1H, s), 4.05 (2H, q), 3.82 (3H, m), 3.04 (2H, m), 2.02 (2H, m), 1.41 (2H, m), 1.18 (3H, t). LC/MS: M+1: 376.

Proceeding as in Reference 14 provided the following compounds:

methyl 3-(4-pyrid-4-ylthiazol-2-ylamino)benzoic acid; HNMR (dmso-d6): 11.00 (1H, s), 8.89 (2H, d), 8.46 (2H, d), 8.38 (1H, s), 7.99 (2H, AB system, d), 7.88 (2H, AB system, d), 3.83 (3H, s), 3.50 (1H, bs);

4-[2-(4-tert-butoxycarbonylpiperazin-1-yl)thiazol-4-yl]benzoic acid; HNMR (dmso-d6): 7.96 (4H, s), 7.50 (1H, s), 3.48 (8H, s), 1.42 (9H, s); and

4-[2-(4-tert-butoxycarbonylpiperazin-1-ylmethyl)thiazol-4-yl]benzoic acid; HNMR (dmso-d6): 8.47 (1H, s), 8.12 (2H, d), 8.03 (2H, d), 4.00 (2H, bs), 3.51 (4H, t), 3.08 (4H, bs), 1.41 (9H, s); LC/MS (M+1): 404.

REFERENCE 15

4-[2-(1-tert-Butoxycarbonylpiperidin-4-ylamino)thiazol-4-yl]benzoic acid

A solution of 4-[2-(1-ethoxycarbonylpiperidin-4-ylamino)thiazol-4-yl]benzoic acid (1 g, 2.66 mmol), provided as in Reference 14, in 30% hydrobromic acid in acetic acid was heated in a sealed vessel at 60°C for approximately 12 hours and then cooled to room temperature. A resulting solid was collected by filtration and washed with diethyl ether to provide 4-(2-piperidin-4-ylaminothiazol-4-yl)benzoic acid hydrobromide (660 mg, 64%). HNMR (dmso-d6): 7.94 (4H, s), 7.31 (1H, s), 4.50 (2H, bs), 3.92 (1H, bs), 3.28 (2H, m), 3.07 (2H, m), 2.15 (2H, m), 1.69 (2H, m). LC/MS: M+1: 304.

A solution of 4-(2-piperidin-4-ylaminothiazol-4-yl)benzoic acid hydrobromide (600 mg, 1.56 mmol) and sodium hydroxide (125 mg, 3.12 mmol) in THF/water (30 mL) was treated with bis(1,1-dimethylethyl) dicarbonate (375 mg, 1.71 mmol). The mixture was stirred for approximately 12 hours at room temperature and then concentrated on a rotavap.

The residue was diluted with water and the mixture was acidified to pH 3 with dilute hydrochloric acid and extracted with ethyl acetate. The extract was washed with brine and dried over $\text{Na}_2(\text{SO})_4$ to provide

4-[2-(1-*tert*-butoxycarbonyl)piperidin-4-ylamino]thiazol-4-yl]benzoic acid (680 mg, 100% yield). HNMR (dms O - d_6): 7.93 (4H, s), 7.73 (1H, d), 7.26 (1H, s), 3.84 (2H, m), 3.76 (1H, m), 2.97 (2H, m), 1.97 (2H, m), 1.46 (9H, s), 1.28 (2H, m).


REFERENCE 16

3-(4-Pyrid-4-ylthiazol-2-ylamino)benzoic acid

A solution of methyl 3-(4-pyrid-4-ylthiazol-2-ylamino)benzoate (500 mg, 1.27 mmol) in a 3/2 mixture of methanol/THF (100 mL) was treated with an aqueous solution of sodium hydroxide ((240 mg, 6 mmol, 20 mL). The reaction mixture was stirred at 40°C for approximately 12 hours and then concentrated. The residue was diluted with water (20 mL) and the diluted solution was acidified to pH 5 with dilute hydrochloric acid. A resulting solid was collected by filtration and washed with water to provide 3-(4-pyrid-4-ylthiazol-2-ylamino)benzoic acid (328 mg, 87% yield). HNMR (dms O - d_6): 10.80 (1H, s), 8.63 (2H, m), 7.90 (7H, m). LC/MS: M+1: 297.86.

EXAMPLE 7

N-(1*S*-Cyanomethylcarbonyl-2-methylbutyl)-4-(2-pyrid-3-ylthiazol-4-yl)benzamide (Compound 331)




A solution of 4-(2-pyrid-3-ylthiazol-4-yl)benzoic acid (1.7 g, 6.03 mmol),

N-cyanomethyl-2*S*-amino-3-methylpentanamide methanesulfonate (1.60 g, 6.03 mmol), and PyBOP (3.14 g, 6.03 mmol) in DMF (20 mL) was treated with 4-methylmorpholine (2.44 g, 24.14 mmol) and the mixture then was stirred at room temperature for 3 hours. The mixture was treated with 10% aqueous potassium carbonate (50 mL) and stirred for an additional 30 minutes, extracted with ethyl acetate (100 mL), washed with saturated aqueous NaHCO₃ (50 mL), dried over MgSO₄, filtered, evaporated, and filtered through a short plug of silica gel (50-100% ethyl acetate/dichloromethane). The most pure fractions were further purified by HPLC to provide *N*-(1*S*-cyanomethylcarbamoyl-2-methylbutyl)-4-(2-pyrid-3-ylthiazol-4-yl)benzamide (89 mg, 13% yield).

EXAMPLE 8

N-(1*S*-Cyanomethylcarbamoyl-3-methylbut-3-enyl)-4-(2-pyrid-3-ylthiazol-4-yl)benzamide
(Compound 332)




A solution of 4-(2-pyrid-3-ylthiazol-4-yl)benzoic acid (0.381 g, 1.35 mmol), *N*-cyanomethyl-2*S*-amino-4-methylpent-4-enamide methanesulfonate (0.355 g, 1.35 mmol) and HBTU (0.511 g, 1.35 mmol) in DMF (10 mL) was treated with 4-methylmorpholine (0.445 mL, 4.04 mmol) and the mixture was stirred at room temperature for approximately 12 hours. The solution was poured into a 4:1:2:3 mixture of ethyl acetate/THF/water/brine (100 mL) and the organic phase was separated, sequentially washed with saturated aqueous NaHCO₃ (50 mL) and brine (50 mL), dried over MgSO₄, filtered and evaporated to dryness. The residue was purified on a short plug of silica gel using ethyl acetate as the mobile phase to provide *N*-(1*S*-cyanomethylcarbamoyl-3-methylbut-3-enyl)-4-(2-pyrid-3-ylthiazol-4-yl)benzamide (100 mg, 17% yield). MS (M+1): 432. NMR (d⁶-

DMSO): 1.74 (3H, s); 2.51-2.54 (2H, m*); 4.16 (2H, d, J = 5.4 Hz); 4.71 (1H, m*); 4.79 (2H, d, J = 9 Hz); 7.61 (1H, dd, J = 8,5 Hz); 8.02 (2H, d, J = 7.7 Hz); 8.19 (2H, d, J = 7.7 Hz); 8.46 (2H, s, d*); 8.65 (1H, d, J = 7 Hz); 8.72 (1H, d, J = 4.7 Hz); 8.79 (1H, t, J = 5.4 Hz); 9.26 (1H, s).

EXAMPLE 10

N-(1-Cyanomethylcarbamoylcyclohexyl)-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide trifluoroacetic acid salt
(Compound 343)



A solution of 4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzoic acid (330 mg, 1 mmol), provided as in Reference 7, in DMF (10 mL) was sequentially treated with trifluoroacetic acid, 1-amino-*N*-cyanomethylcyclohexanecarboxamide methanesulfonic acid salt (300 mg, 1.0 mmol), provided as in Reference 9, triethylamine (0.5 mL, 3 mmol) and HATU (400 mg, 1 mmol). The solution was stirred for approximately 12 hours and then diluted with ethyl acetate (50 mL) and saturated sodium bicarbonate (20 mL). The ethyl acetate layer was separated and concentrated. Product was purified from the residue by preparative reverse phase HPLC to provide *N*-(1-cyanomethylcarbamoylcyclohexyl)-4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide trifluoroacetic acid salt (200 mg, 40 %). ¹H NMR (DMSO-*d*₆, ppm): 1.55-1.72 (m, 6 H), 2.11-2.23 (m, 2 H), 2.81 (s, 3 H), 3.21-3.67 (m, 6 H), 4.89-4.13 (m, 5 H), 7.51 (s, 1 H), 8.03 (m, 4 H), 8.13 (m, 1 H). ES-
Ms: 466.4 (M+H⁺).


Proceeding as in Example 10 provided the following compounds of the Invention:

N-[1-(4-cyanotetrahydropyran-4-yl)carbamoyl]cyclohexyl]-4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide (Compound 344); ^1H NMR (DMSO- d_6 , ppm): 1.25-1.42 (m, 4 H), 1.55-1.91 (m, 6 H), 2.81 (s, 3 H), 3.11-3.87 (m, 10 H), 4.17-4.23 (m, 2 H), 7.51 (s, 1 H), 7.88 (m, 5 H); ES-MS: 537.1 ($\text{M}+\text{H}^+$); and

5 *N*-(1-cyanomethylcarbamoyl)cyclohexyl)-4-(2-morpholin-4-ylthiazol-4-yl)benzamide (Compound 345); ^1H NMR (DMSO- d_6 , ppm): 1.51-1.74 (m, 6 H), 2.11-2.23 (m, 4 H), 3.21-3.67 (m, 8 H), 4.17-4.23 (m, 2 H), 7.51 (s, 1 H), 8.03 (m, 4 H), 8.13 (m, 1 H); ES-MS: 454.0 ($\text{M}+\text{H}^+$).

EXAMPLE 11

N-(1*S*-Cyanomethylcarbamoyl-3-methylbutyl)-4-[2-(1-methylpyrid-3-yl)thiazol-4-yl]benzamide iodide salt
(Compound 346)



A solution of *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-4-(2-pyrid-3-ylthiazol-4-yl)benzamide (80 mg, 0.184 mmol), provided as in Reference 12, in acetonitrile (1 mL) was treated with methyl iodide (115 μL , 1.84 mmol, 10 eq.) added dropwise. The reaction mixture was stirred for approximately 72 hours and then concentrated to dryness. The residue treated with ethyl ether. The solid was collected by filtration and washed with the same diethyl ether to provide solvent

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-[2-(1-methylpyrid-3-yl)thiazol-4-yl]benzamide iodide salt (85 mg, 80 % yield). HNMR (dmso- d_6): 9.74 (1H, s), 9.15 (1H, d), 9.07 (1H, d), 8.78 (1H, t), 8.68 (1H, d), 8.65 (1H, s), 8.24 (3H, m), 8.07 (2H, d), 4.58 (1H, m), 4.48 (3H, s), 4.15 (2H, d), 1.70 (3H, m), 0.91

(6H, m). M: 448).

Proceeding as in Example 11 provided the following compounds of the Invention:

4-[2-(1-carbamoylmethylpyridin-3-yl)thiazol-4-yl]-N-(1S-cyanomethylcarbamoyl-3-methylbutyl)benzamide bromide salt (Compound 347); HNMR (dmso-d₆): 9.78 (1H, s), 9.21 (1H, d), 9.06 (1H, d), 8.78 (1H, t), 8.68 (1H, d), 8.66 (1H, s), 8.33 (1H, dd), 8.24 (2H, d), 8.08 (3H, m), 7.79 (1H, s), 5.55 (2H, s), 4.55 (1H, m), 4.15 (2H, d), 1.70 (3H, m), 0.91 (6H, m). M: 491; LC/MS, M: 491;


N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-[2-(1-methylpyridin-4-ylamino)thiazol-4-yl]benzamide iodide salt (Compound 348); HNMR (dmso-d₆): 8.76 (1H, t), 8.63 (3H, m), 8.10 (3H, m), 8.03 (2H, d), 7.97 (1H, s), 4.57 (1H, m), 4.15 (2H, d), 4.14 (3H, s), 1.70 (3H, m), 0.91 (6H, m);

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-[2-(1-methylpyridin-4-yl)thiazol-4-yl]benzamide iodide salt (Compound 349); HNMR (dmso-d₆): 9.09 (2H, d), 8.83 (1H, s), 8.73 (2H, d), 8.25 (2H, d), 8.08 (2H, d), 4.58 (1H, m), 4.52 (3H, s), 4.16 (2H, s), 1.70 (3H, m), 0.92 (6H, m); and

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-[2-(1-allylpyrid-4-yl)thiazol-4-yl]benzamide bromide salt (Compound 350).

EXAMPLE 12

Ethyl 4-{4-[4-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate (Compound 351)



A solution of 4-[2-(1-*tert*-butoxycarbonylpiperidin-4-ylamino)thiazol-4-yl]benzoic

acid (751 mg, 2 mmol), provided as in Reference 15, and methane sulfonate salt of 2S-amino-N-cyanomethyl-4-methylpentanamide (560 mg, 2 mmol) in DMF (10 mL) was treated with PyBOP (1.04 mg, 2 mmol) and diisopropylethylamine (715 μ L, 4.1 mmol) at room temperature. The mixture was stirred overnight and then concentrated under vacuum. The residue was dissolved in ethyl acetate and the solution was washed sequentially with saturated NaHCO₃ solution and brine, dried on sodium sulfate and concentrated. Product was purified from the residue by silica gel column, using ethyl acetate/hexanes as eluent, to provide ethyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]phenyl}thiazol-2-ylamino}piperidine-1-carboxylate (815 mg, 77% yield); HNMR (dmso-d₆): 8.71 (1H, t), 8.54 (1H, d), 7.91 (4H, AB system, dd), 7.74 (1H, d), 7.23 (1H, s), 4.52 (1H, m), 4.13 (2H, t), 4.04 (2H, q), 3.90 (2H, m), 3.76 (1H, m), 3.04 (2H, m), 1.98 (2H, m), 1.65 (3H, m), 1.38 (2H, m), 1.18 (3H, t), 0.89 (6H, m). LC/MS: M+1: 527.

Proceeding as in Example 12 provided ethyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]phenyl}thiazol-2-ylamino}piperidine-1-carboxylate (Compound 252); HNMR (dmso-d₆): 8.71 (1H, t), 8.54 (1H, d), 7.91 (4H, dd), 7.73 (1H, d), 7.23 (1H, s), 4.52 (1H, m), 4.13 (2H, m), 3.85 (2H, m), 3.75 (1H, m), 3.00 (2H, m), 1.95 (2H, m), 1.70 (3H, m), 1.40 (9H, s), 1.37 (2H, m), 0.88 (6H, m); LC/MS: M+1: 555;

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-(4-pyrid-4-ylthiazol-2-ylamino)benzamide (Compound 353); HNMR (dmso-d₆): 10.6 (1H, s), 8.67 (1H, t), 8.63 (2H, AB system, d), 8.38 (1H, d), 7.95 (2H, AB system, d), 7.88 (2H, AB system, d), 7.82 (2H, AB system, d), 7.81 (1H, s), 4.49 (1H, m), 4.13 (2H, d), 1.70 (3H, m), 0.89 (6H, m); LC-MS: M+1: 449;

tert-butyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]phenyl}thiazol-2-yl}piperazine-1-carboxylate (Compound 354); HNMR (dmso-d₆): 8.72 (1H, t), 8.57 (1H, d), 7.94 (4H, s), 7.48 (1H, s), 4.52 (1H, m), 4.13 (2H, d), 3.48 (8H, s), 1.65 (3H, m), 0.89 (6H, m). LC/MS: M+1: 541;

tert-butyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]phenoxyethyl}thiazol-2-yl}piperazine-1-carboxylate (Compound 355); HNMR (dmso-d₆): 8.66 (1H, t), 8.40 (1H, d), 7.89 (2H, d), 7.08 (2H, d),

6.90 (1H, s), 4.99 (2H, s), 4.48 (1H, m), 4.11 (2H, d), 3.41 (8H, m), 1.65 (3H, m), 0.88 (6H, m);

tert-butyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]piperidin-1-ylmethyl}thiazol-2-yl}piperazine-1-carboxylate (Compound 356); HNMR (dmso-d₆): 8.71 (1H, t), 8.17 (1H, d), 7.03 (1H, s), 4.26 (1H, m), 4.16 (2H, bs), 4.11 (2H, d), 3.79 (4H, bs), 3.45 (4H, bs), 2.97 (2H, bs), 2.43 (1H, m), 1.85 (3H, m), 1.46 (3H, m), 1.41 (9H, s); LC/MS: M+1: 562.4;

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-(4-morpholin-4-ylmethylthiazol-2-ylamino)benzamide (Compound 357); HNMR (dmso-d₆): 10.7 (1H, s), 8.72 (1H, t), 8.39 (1H, d), 7.91 (2H, d), 7.71 (2H, d), 7.19 (1H, s), 4.50 (1H, m), 4.34 (2H, s), 4.12 (2H, m), 3.59 (8H, m), 1.65 (3H, m), 0.89 (6H, m); LC/MS: M+1: 471;

tert-butyl 4-{2-[4-(1S-cyanomethylcarbamoyl)-3-methylbutylcarbamoyl]phenylamino}thiazol-4-ylmethyl}piperazine-1-carboxylate (Compound 358);

tert-butyl 4-(4-{4-[1S-(1-cyanocyclopropylcarbamoyl)-3-methylbutylcarbamoyl]phenyl}thiazol-2-yl)piperazine-1-carboxylate (Compound 359); HNMR (dmso-d₆): 8.98 (1H, s), 8.51 (1H, d), 7.92 (4H, m), 7.47 (1H, s), 4.44 (1H, m), 3.48 (8H, s), 1.65 (2H, m), 1.48 (3H, m), 1.43 (9H, s), 1.12 (2H, m), 0.89 (6H, m); LC/MS: M+1: 567.5;

tert-butyl 4-(4-{4-[1S-(N-cyanomethyl-N-methylcarbamoyl)-3-methylbutylcarbamoyl]phenyl}thiazol-2-yl)piperazine-1-carboxylate (Compound 360); HNMR (dmso-d₆): 8.70 (1H, d), 7.92 (4H, s), 7.47 (1H, s), 4.93 (1H, m), 4.41 (2H, m), 3.48 (8H, s), 3.20 and 2.91 (3H, s), 1.75 (2H, m), 1.42 (1H, m), 1.42 (9H, s), 0.93 (6H, bs); LC/MS: M+1: 555.5;

N-[1S-(N-cyanomethyl-N-methylcarbamoyl)-3-methylbutyl]-4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide (Compound 361); HNMR (dmso-d₆): 8.71 (1H, d), 7.98 and 7.95 (4H, m), 7.60 and 7.58 (1H, s), 4.93 (1H, m), 4.42 (2H, m), 4.12 (2H, m), 3.53 (6H, m), 2.87 (3H, s), 1.74 (2H, m), 1.45 (1H, m), 0.93 (6H, m); LC/MS: M+1: 468.4; and

tert-butyl 4-(4-{4-[1S-(1-cyanocyclopropylcarbamoyl)-

3-methylbutylcarbamoylphenyl}thiazol-2-ylmethyl)piperazine-1-carboxylate


(Compound 362); HNMR (dms_o-d₆): 8.22 (1H, s), 8.00 (5H, m), 4.45 (1H, m), 3.92 (2H, s), 3.36 (4H, m), 2.50 (4H, m), , 1.65 (2H, m), 1.48 (3H, m), 1.40 (9H, s), 1.12 (2H, m), 0.89 (6H, m).

5

EXAMPLE 13tert-Butyl4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-yl}piperazine-1-carboxylate

10

(Compound 363)



15


A solution of 1-amino-*N*-cyanomethylcyclohexanecarboxamide (500 mg, 1.8 mmol), provided as in Reference 9, and 4-[2-(4-*tert*-butoxycarbonylpiperazin-1-yl)thiazol-4-yl]benzoic acid (702 mg, 1 mmol), provided as in Reference 14, in DMF was treated with diisopropylethylamine (940 μ L, 5.4 mmol) and HATU (685 mg, 1.8 mmol). The mixture was stirred for approximately 12 hours at room temperature and then concentrated under vacuum. The residue was dissolved in ethyl acetate and the solution was washed sequentially with saturated solution of NaHCO₃, water and brine, dried over Na₂SO₄ and concentrated. Product was purified from the residue through silica gel to provide tert-butyl 4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-yl}piperazine-1-carboxylate (350 mg, 35% yield) as a foam. HNMR (dms_o-d₆): 8.31 (1H, t), 8.09 (1H, s), 8.02 (4H, dd), 7.57 (1H, s), 4.15 (2H, d), 3.58 (8H, s), 2.13 (2H, m), 1.76 (2H, m), 1.53 (4H, m), 1.43 (9H, s), 1.40 (2H, m). LC/MS: M+1: 553.

25

Proceeding as in Example 13 provided *tert*-butyl
 4-(4-{4-[1-cyanomethylcarbamoyl]cyclohexylcarbamoyl}phenyl}thiazol-2-ylmethyl)piperazine-1-carboxylate (Compound 364); HNMR (dms_o-d₆): 8.22 (1H, m), 8.00 (4H, m), 7.47 (1H, d), 4.04 (2H, m), 3.92 (2H, s), 3.37 (4H, m), 2.50 (4H, m), 2.13 (2H, m), 1.75 (2H, m), 1.54 (5H, m), 1.40 (9H, s), 1.40 (2H, m); LC/MS: M+1: 567.4

EXAMPLE 14

N-(1*S*-Cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide methanesulfonic acid salt
 (Compound 365)



A solution of ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate (290 mg, 0.52 mmol), prepared as in Example 12, in dry THF (5 mL) was treated with methanesulfonic acid (135 μ L, 2.08 mmol, 4 eq) at room temperature. The mixture was stirred overnight and then diluted with diethyl ether. The resulting solid was collected by filtration and triturated with several portions of diethyl ether. Product was purified from the crude solid by reversed phase preparative TLC, using a mixture of acetonitrile/water (8/2) as the mobile phase, to provide *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide methanesulfonic acid salt (90 mg, 31% yield). HNMR (dms_o-d₆): 8.73 (1H, t), 8.54 (1H, d), 7.92 (4H, s), 7.85 (1H, d), 7.27 (1H, s), 4.51 (1H, m), 4.13 (2H, t), 3.88 (1H, m), 3.25 (2H, m), 3.03 (2H, m), 2.30 (3H, s), 2.15 (2H, m), 1.65 (5H, m), 0.89 (6H, m). LC/MS: M+1: 455.

Proceeding as in Example 14 provided the following compounds of the Invention:

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-

4-(2-piperazin-1-ylthiazol-4-yl)benzamide (Compound 366); HNMR (dmso-d6): 8.96 (1H, bs), 8.74 (1H, t), 8.58 (1H, d), 7.95 (4H, s), 7.56 (1H, s), 4.52 (1H, m), 4.13 (2H, d), 3.71 (4H, m), 3.28 (4H, bs), 1.65 (3H, m), 0.89 (6H, m);

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-

4-(2-piperazin-1-ylthiazol-4-ylmethoxy)benzamide (Compound 367); HNMR (dmso-d6): 8.67 (1H, t), 8.40 (1H, d), 7.89 (2H, d), 7.07 (2H, d), 6.99 (1H, s), 4.99 (1H, s), 4.48 (1H, m), 4.11 (2H, d), 3.56 (4H, m), 3.18 (4H, m), 1.65 (3H, m), 0.89 (6H, m); LC/MS: M+1: 471;

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-

1-(2-piperazin-1-ylthiazol-4-ylmethyl)piperidine-4-carboxamide (Compound 368); HNMR (dmso-d6): 9.10 (1H, bs), 8.67 (1H, t), 8.15 (1H, s), 7.09 (1H, s), 4.25 (1H, m), 4.10 (2H, d), 3.63 (2H, bs), 3.35 (4H, bs), 3.24 (4H, m), 2.92 (2H, bs), 2.36 (7H, m), 1.80 (3H, m), 1.44 (3H, m), 0.83 (6H, m); LC/MS: M+1: 462.3;

N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-

4-(4-piperazin-1-ylmethylthiazol-2-ylamino)benzamide (Compound 369); HNMR (dmso-d6): 10.4 (1H, s), 8.68 (1H, t), 8.48 (1H, bs), 8.35 (1H, d), 7.88 (2H, d), 7.67 (2H, d), 4.48 (1H, m), 4.12 (2H, d), 3.58 (2H, s), 3.10 (4H, bs), 2.69 (4H, bs), 2.34 (6H, s), 1.65 (3H, m), 0.88 (6H, m);

N-[1S-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-

4-(2-piperazin-1-yl-thiazol-4-yl)benzamide (Compound 370); HNMR (dmso-d6): 8.99 (1H, s), 8.52 (1H, d), 7.94 (4H, s), 7.53 (1H, s), 4.44 (1H, m), 3.65 (4H, m), 3.20 (4H, m), 1.65 (2H, m), 1.47 (3H, m), 1.11 (2H, m), 0.88 (6H, m); LC/MS: M+1: 467.2;

N-[1S-(N-cyanomethyl-N-methylcarbamoyl)-3-methylbutyl]-

4-(2-piperazin-1-ylthiazol-4-yl)benzamide (Compound 371); HNMR (dmso-d6): 8.69 (1H, d), 7.94 (4H, m), 7.53 (1H, s), 4.93 (1H, m), 4.41 (2H, dd), 3.66 (4H, m), 3.30 (4H, m), 3.20 and 2.90 (3H, s), 1.70 (2H, m), 1.45 (1H, m), 0.93 (6H, m); LC/MS: M+1: 455.1;

N-(1-cyanomethylcarbamoylcyclohexyl)-4-(2-piperazin-1-ylthiazol-4-yl)benzamide

(Compound 372); HNMR (dmso-d6): 8.90 (1H, bs), 8.21 (1H, m), 7.94 (5H, m), 7.56 (1H, d), 4.06 (2H, d), 3.71 (4H, m), 3.29 (4H, bs), 2.13 (2H, m), 1.76 (2H, m), 1.54 (5H, m),

1.29 (1H, m). LC/MS: M+1: 453.2; and

N-(1-cyanomethylcarbamoylcyclohexyl)-

4-(2-piperazin-1-ylmethylthiazol-4-yl)benzamide (Compound 373); HNMR (dmso-d₆):

8.26 (1H, s), 8.24 (1H, d), 8.05 (1H, s), 4.06 (2H, d), 4.01 (2H, s), 3.15 (4H, m), 2.77 (4H,


5 m), 2.15 (2H, m), 1.75 (2H, m), 1.54 (5H, m), 1.30 (1H, m). LC/MS: M+1: 467.2.

EXAMPLE 15

Ethyl 4-{4-[4-(1S-cyanomethylcarbamoyl)-

3-methylbutylcarbamoyl]phenyl]thiazol-2-yl}piperazine-1-carboxylate


10 (Compound 374)



15 A solution of N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperazin-1-ylthiazol-4-yl)benzamide (200 mg, 0.35 mmol), provided as in Example
 14, in a 5:1 mixture of dry THF/DMF was treated with diisopropylethylamine (146 μ L,
 0.84 mmol) and ethyl chloro formate (40 mL, 0.42 mmol). The mixture was stirred for 16
 hours at room temperature and then diluted with ethyl acetate. The dilution was acidified
 20 with 1 N hydrochloric acid, washed with brine, dried over sodium sulfate and concentrated.
 Crude product was purified from the residue by preparative TLC to provide ethyl
4-{4-[4-(1S-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl]thiazol-2-yl}piperazine-1-carboxylate. HNMR (dmso-
 d₆): 8.73 (1H, t), 8.57 (1H, d), 7.94 (4H, s), 7.48 (1H, s), 4.53 (1H, m), 4.13 (2H, d), 4.08
 25 (2H, q), 3.52 (8H, m), 1.65 (3H, m), 1.21 (3H, t) 0.89 (6H, m).

EXAMPLE 16

N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-benzylpiperazine-1-carboxamide trifluoroacetic acid salt
(Compound 383)



A solution of 4-amino-*N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)benzamide (1.7 g, 6 mmol) in dichloromethane (120 mL) and acetonitrile (60 mL) was warmed and treated with aqueous sodium bicarbonate solution (100 mL). The mixture was cooled to 0 °C with vigorous stirring and then allowed to settle into two layers briefly. The bottom layer was treated at once with a 20% phosgene solution in toluene (10 mL, 18 mmol). The mixture was stirred vigorously for 10 minutes at 0 °C. One twelfth of the mixture was added to a solution of 1-benzylpiperazine (0.17 mL, 10 mmol) in acetonitrile (5 mL) and after stirred for 20 h, the mixture was extracted with dichloromethane. The extract was dried over anhydrous sodium sulfate, filtered, and evaporated. The crude product was purified by reverse phase HPLC on a C-18 column to provide

N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-benzylpiperazine-1-carboxamide trifluoroacetic acid salt (as a white solid (0.14 g, 46% yield). ¹H NMR (270 MHz, DMSO-*d*₆) δ 0.84 (d, 3), 0.88 (d, 3), 1.47 - 1.75 (m, 3), 3.1 - 3.4 (m, 6), 4.10 (t, 2), 4.2 - 4.3 (m, 2), 4.35 (br. s, 2), 4.48 (m, 1), 7.48 (br. s, 5), 7.52 (d, 2), 7.82 (d, 2), 8.36 (d, 1 NH), 8.68 (t, 1 NH), 9.01 (s, 1 NH), 10.1 (br. s, 1); ESI-MS *m/z* 491.4 (*M*+1).

Proceeding as in Example 16 provided the following compounds of the Invention:

3-[3-(1-benzylpyrrolidin-3-yl)-3-methylureido]-N-(1S-cyanomethylcarbamoyl)-3-methylbutyl)benzamide (Compound 375); ¹H NMR (270 MHz, DMSO-d₆, mixture of diastereomers) δ 0.86 (d, 3), 0.90 (d, 3), 1.47 - 1.77 (m, 3), 2.0 - 2.4 (m, 2), 2.95 and 2.97 (s, 3), 3.1 - 3.7 (m, 4), 4.12 (d, 2), 4.25 - 4.53 (m, 3), 4.7 - 4.9 (m, 1), 7.30 - 7.37 (m, 1), 7.45 - 7.53 (m, 6), 7.91 (s, 1), 8.47 (d, 1), 8.59 (s, 1), 8.72 (m, 1); ESI-MS m/z 505.2 (M+1);

N-[4-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-morpholin-4-ylethyl)piperazine-1-carboxamide (Compound 376); ¹H NMR (270 MHz, DMSO-d₆) δ 0.89 (d, 3), 0.91 (d, 3), 1.48 - 1.75 (m, 3), 2.9 - 3.2 (m, 12), 3.6 - 3.8 (m, 8), 4.12 (d, 2), 4.51 (m, 1), 7.34 (t, 1), 7.54 (d, 1), 7.68 (dd, 1), 7.89 (t, 1), 8.47 (d, 1 NH), 8.71 (t, 1 NH), 8.81 (s, 1 NH); ESI-MS m/z 514.2 (M+1);

N-[3-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-morpholin-4-ylethyl)piperazine-1-carboxamide (Compound 377); ¹H NMR (270 MHz, DMSO-d₆) δ 0.87 (d, 3), 0.90 (d, 3), 1.48 - 1.76 (m, 3), 2.9 - 3.2 (m, 12), 3.6 - 3.8 (m, 8), 4.12 (d, 2), 4.48 (m, 1), 7.55 (d, 2), 7.83 (d, 2), 8.36 (d, 1 NH), 8.70 (t, 1 NH), 8.91 (s, 1 NH); ESI-MS m/z 514.2 (M+1);

4-[3-(1-benzylpiperidin-4-yl)ureido]-N-(1S-cyanomethylcarbamoyl)-3-methylbutyl)benzamide (Compound 378); ¹H NMR (270 MHz, DMSO-d₆) δ 0.82 (d, 3), 0.86 (d, 3), 1.45 - 1.73 (m, 5), 1.88 - 2.06 (m, 2), 3.0 - 3.1 (m, 2), 3.30 - 3.37 (m, 2), 3.7 - 3.9 (m, 1), 4.09 (d, 2), 4.2 - 4.3 (m, 2), 4.44 (m, 1), 6.60 (d, 1 NH), 7.42 (d, 2), 7.46 (m, 5), 7.78 (d, 2), 8.31 (d, 1), 8.66 (m, 1), 8.73 (m, 1); ESI-MS m/z 505.2 (M+1);

4-[3-(1-benzylpyrrolidin-3S-yl)-3-methylureido]-N-(1S-cyanomethylcarbamoyl)-3-methylbutyl)benzamide trifluoroacetic acid salt (Compound 379); ¹H NMR (270 MHz, DMSO-d₆, mixture of rotomers) δ 0.87 (d, 3), 0.91 (d, 3), 1.48 - 1.75 (m, 3), 2.0 - 2.4 (m, 2), 2.96 and 2.99 (s, 3), 3.1 - 3.7 (m, 4), 4.13 (d, 2), 4.25 - 4.53 (m, 3), 4.82 - 4.92 (m, 1), 7.47 - 7.58 (m, 7), 7.82 - 7.86 (m, 2), 8.37 (d, 1 NH), 8.66 - 8.71 (m, 2), 9.94 (br. s, 1); ESI-MS m/z 505.1 (M+1);

4-[3-(1-benzylpyrrolidin-3R-yl)-3-methylureido]-N-(1S-cyanomethylcarbamoyl)-3-methylbutyl)benzamide trifluoroacetic acid salt (Compound 380); ¹H NMR (270 MHz, DMSO-d₆, mixture of rotomers) δ 0.87 (d, 3), 0.91 (d, 3), 1.48 - 1.76 (m, 3), 2.0 - 2.4 (m, 2), 2.96 and 2.99 (s, 3), 3.1 - 3.7 (m, 4), 4.13 (d, 2), 4.35 - 4.53 (m, 3), 4.8 - 4.9 (m, 1),

7.47 – 7.57 (m, 7), 7.82 – 7.86 (m, 2), 8.37 (d, 1 NH), 8.66 – 8.71 (m, 2), 9.9 (br. s, 1);
ESI-MS m/z 505.1 (M+1);

N-[4-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-pyrimidin-2-ylpiperazine-1-carboxamide (Compound 381); ¹H NMR (270 MHz, DMSO-
5 d₆) δ 0.87 (d, 3), 0.91 (d, 3), 1.48 - 1.75 (m, 3), 3.55 – 3.58 (m, 4), 3.77 - 3.80 (m, 4), 4.12
(d, 2), 4.48 (m, 1), 6.68 (t, 1), 7.58 (d, 2), 7.84 (d, 2), 8.37 (d, 1 NH), 8.40 (d, 2), 8.68 (t, 1
NH), 8.88 (s, 1 NH); ESI-MS m/z 479 (M+1);

N-[4-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-oxo-
2-pyrrolidin-1-ylethyl)piperazine-1-carboxamide (Compound 382); ¹H NMR (270 MHz,
10 DMSO-d₆) δ 0.86 (d, 3), 0.91 (d, 3), 1.49 - 1.98 (m, 7), 3.0 – 3.6 (m, 8), 4.12 (t, 2), 4.22
(br. s, 4), 4.48 (m, 1), 7.55 (d, 2), 7.86 (d, 2), 8.38 (d, 1 NH), 8.70 (t, 1 NH), 9.04 (s, 1
NH); ESI-MS m/z 512.3 (M+1);

N-[3-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-pyrimidin-2-ylpiperazine-1-carboxamide (Compound 384); ¹H NMR (270 MHz, DMSO-
15 d₆) δ 0.86 (d, 3), 0.90 (d, 3), 1.47 - 1.77 (m, 3), 3.52 - 3.56 (m, 4), 3.75 - 3.79 (m, 4), 4.11
– 4.13 (t, 3), 4.50 (m, 1), 6.66 (t, 1), 7.32 (t, 1), 7.50 (d, 1), 7.69 (d, 1), 7.91 (s, 1), 8.39 (d,
2), 8.45 (d, 1 NH), 8.68 (t, 1 NH), 8.78 (s, 1 NH); ESI-MS m/z 479.3 (M+1);

N-[3-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-oxo-
2-pyrrolidin-1-ylethyl)piperazine-1-carboxamide trifluoroacetic acid salt (Compound 385);
20 ¹H NMR (270 MHz, DMSO-d₆) δ 0.87 (d, 3), 0.91 (d, 3), 1.49 - 1.98 (m, 7), 3.0 – 3.6 (m,
8), 4.13 (d, 2), 4.21 (br. s, 4), 4.50 (m, 1), 7.36 (t, 1), 7.56 (d, 1), 7.69 (d, 1), 7.89 (s, 1),
8.48 (d, 1 NH), 8.72 (t, 1 NH), 8.95 (s, 1 NH), 10.1 (br. s, 1); ESI-MS m/z 512.4 (M+1);

N-[3-(1S-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-benzylpiperazine-1-carboxamide trifluoroacetic acid salt (Compound 386); ¹H NMR
25 (270 MHz, DMSO-d₆) δ 0.87 (d, 3), 0.91 (d, 3), 1.47 - 1.78 (m, 3), 3.0 – 3.2 (m, 4), 3.36 –
3.40 (m, 2), 4.13 (d, 2), 4.2 – 4.3 (m, 2), 4.38 (br. s, 2), 4.51 (m, 1), 7.36 (t, 1), 7.51 (br. s,
5), 7.56 (d, 1), 7.69 (d, 1), 7.89 (s, 1), 8.48 (d, 1 NH), 8.72 (t, 1 NH), 8.93 (s, 1 NH), 9.8
(br. s, 1); ESI-MS m/z 491.4 (M+1); and

3-[3-(1-benzylpiperidin-4-yl)ureido]-N-(1S-cyanomethylcarbamoyl-
30 3-methylbutyl)benzamide trifluoro acetic acid salt (Compound 387); ¹H NMR (270 MHz,
DMSO-d₆) δ 0.87 (d, 3), 0.91 (d, 3), 1.45 - 1.78 (m, 5), 1.93 – 2.11 (m, 2), 3.02 – 3.15 (m,

2), 3.30 – 3.37 (m, 2), 3.7 – 3.9 (m, 1), 4.13 (d, 2), 4.29 – 4.38 (m, 2), 4.48 (m, 1), 6.54 (d, 1 NH), 7.31 (t, 1), 7.46 (d, 1), 7.50 (br. s, 5), 7.59 (d, 1), 7.80 (s, 1), 8.47 (d, 1 NH), 8.59 (s, 1 NH), 8.70 (t, 1 NH), 9.46 (br. s, 1); ESI-MS m/z 505.4 ($M+1$).

5

Proceeding in a fashion analogous to the procedures exemplified above provided the following compounds of the Invention:

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

10 4-(2-pyrid-4-ylamino)thiazol-4-ylbenzamide (Compound 335); ^1H NMR (DMSO- d_6 , ppm): 0.91 (m, 6 H), 1.65 (m, 3 H), 4.01 (m, 2 H), 4.37 (m, 1 H), 7.82-8.03 (m, 7 H), 8.73 (m, 3 H), 8.91 (m, 1 H); ES- M_s : 448.9 ($M+H^+$);

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

15 4-(2-pyrid-4-ylthiazol-4-yl)benzamide (Compound 336); ^1H NMR (DMSO- d_6 , ppm): 0.91 (m, 6 H), 1.55-1.72 (m, 3 H), 4.17 (m, 2 H), 4.31 (m, 1 H), 8.03-8.63 (m, 7 H), 8.83 (m, 2 H), 8.91 (m, 1 H), 8.98-9.11 (m, 2 H); ES- M_s : 443.9 ($M+H^+$);

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

20 4-(2-pyrid-2-ylamino)thiazol-4-ylbenzamide (Compound 337); ^1H NMR (DMSO- d_6 , ppm): 0.91 (m, 6 H), 1.65 (m, 3 H), 4.01 (m, 2 H), 4.37 (m, 1 H), 6.91-7.11 (m, 2 H), 7.60 (m, 1 H), 7.11 (m, 1 H), 7.59 (d, 1 H), 7.72 (d, 1 H), 8.03 (m, 4 H), 8.32 (m, 1 H), 8.59 (m, 1 H), 8.73 (m, 1 H); ES- M_s : 448.9 ($M+H^+$);

N-[4-[4-(1*S*-cyanomethylcarbamoyl)-

25 3-methylbutylcarbamoyl]phenyl]thiazol-2-yl]isonicotinamide (Compound 338); ^1H NMR (DMSO- d_6 , ppm): 0.95 (m, 6 H), 1.65-1.78 (m, 3 H), 4.17 (m, 3 H), 8.01-8.15 (m, 5 H), 8.60-8.79 (m, 4 H); ES- M_s : 477.2 ($M+H^+$);

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

30 4-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]benzamide (Compound 339); ^1H NMR (DMSO- d_6 , ppm): 0.95 (m, 6 H), 1.65-1.78 (m, 3 H), 3.11-3.67 (m, 16 H), 3.78-3.85 (m, 4 H), 4.17 (s, 2 H), 4.45 (m, 1 H), 7.01 (d, 2 H), 8.01 (d, 2 H), 8.40 (m, 1 H), 8.79 (m, 1 H); ES- M_s : 471.2 ($M+H^+$);

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

4-(4-pyrid-4-ylpiperazin-1-yl)benzamide (Compound 340); ¹H NMR (DMSO-d₆, ppm): 0.95 (m, 6 H), 1.65-1.78 (m, 3 H), 3.67-3.87 (m, 8 H), 4.17 (s, 2 H), 4.38 (m, 1 H), 6.81 (d, 2 H), 7.21 (d, 2 H), 7.78 (d, 2 H), 8.20 (d, 2 H), 8.79 (m, 1 H); ES-MS: 435.2 (M+H⁺);
N-[1S-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-

5 4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide (Compound 341); ¹H NMR (DMSO-d₆, ppm): 0.91 (m, 6 H), 1.55-1.72 (m, 3 H), 2.81 (s, 3 H), 3.21-3.87 (m, 8 H), 4.17 (m, 2 H), 4.31 (m, 1 H), 7.51 (s, 1 H), 8.03 (m, 4 H), 8.83 (m, 2 H), 8.61 (m, 1 H), 9.11 (m, 1 H); ES-MS: 480.9 (M+H⁺); N-(1R-cyanomethylcarbamoyl-3-methylbutyl)-

10 4-(2-morpholin-4-ylthiazol-4-yl)benzamide (Compound 342); ¹H NMR (DMSO-d₆, ppm): 0.91 (m, 6 H), 1.55-1.72 (m, 3 H), 3.15-3.27 (m, 4 H), 3.61-3.87 (m, 4 H), 4.17 (m, 2 H), 4.51 (m, 1 H), 7.51 (s, 1 H), 7.72 (m, 1 H), 8.03 (m, 4 H), 8.61 (m, 1 H), 8.81 (m, 1 H); ES-MS: 441.2 (M+H⁺).

4-(2-pyrid-3-ylthiazol-4-yl)benzyl 1S-cyanomethylcarbamoyl-3-methylbutylcarbamate (Compound 388);

15 N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide (Compound 389);
N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-[N-methyl-N-(4-pyrid-4-ylthiazol-2-yl)amino]benzamide (Compound 390);

tert-butyl

20 4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenoxy]methyl}thiazol-2-yl}piperazine-1-carboxylate (Compound 391); NMR (in DMSO-d₆): δ 8.14 (m, 1H), δ 7.87-7.78 (m, 3H), δ 7.1-7.0 (m, 2H), δ 6.87 (s, 1H), δ 4.95 (s, 1H), δ 4.00 (s, br, 2H), δ 3.81-3.48 (m, 8H), δ 1.71-1.31 (m, 19H); MS: M+ H⁺ = 583.2;

tert-butyl 4-(4-{4-[1S-(1-cyanocyclopropylcarbamoyl)-

25 3-methylbutylcarbamoyl]phenyl}thiazol-2-ylamino)piperidine-1-carboxylate (Compound 392); ¹H NMR (DMSO): 8.97 (s, 1H), 8.49 (d, 1H), 7.90 (s, 4H), 7.73 (d, 1H), 7.23 (s, 1H), 4.43 (m, 1H), 3.85 (d, 2H), 3.75 (m, 1H), 2.98 (m, 2H), 1.97 (m, 2H), 1.81 (m, 1H), 1.68 (m, 2H), 1.48 (dd, 2H), 1.41 (br s, 11H), 1.11 (dd, 2H), 0.89 (m, 6H); MS: (m=z) 581.4;

30 N-[1S-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide (Compound 393); ¹H NMR (DMSO): 8.99

(s, 1H), 8.50 (d, 1H), 7.91 (s, 4H), 7.87 (d, 1H), 7.27 (s, 1H), 4.43 (m, 1H), 3.89 (m, 1H), 3.32 (m, 2H), 3.04 (m, 2H), 2.33 (s, 3H), 2.16 (m, 2H), 1.72 (m, 5H), 1.48 (dd, 2H), 1.11 (dd, 2H), 0.89 (m, 6H); MS: (m=z) 481.0;

tert-butyl

5 4-[4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-ylamino]piperidine-1-carboxylate (Compound 394); NMR (in DMSO-d₆): δ 8.31-7.76 (m, 6H), δ 7.2 (s, 1H), δ 4.20-3.60 (m, 23H), δ 2.94 (s, br, 1H), δ 2.12-1.05 (m, 21H); MS: M+ H⁺ = 567.4;

N-[1-(Cyanomethyl-carbamoyl)-2-methyl-butyl]-4-[2-(pyridin-3-ylamino)-thiazol-4-yl]-benzamide (Compound 395); MS: 449 (M+1); ¹H NMR (DMSO-d₆): 0.9 (6H, t + d), 1.23 (1H, m), 1.52 (1H, m), 2.00 (1H, m), 4.2 (2H, br d), 4.3 (1H, t, 7Hz), 7.64 (1H, s), 7.7 (1H, m), 7.95-8.1 (4H, 2xd, J=7 Hz), 8.4-8.6 (3H, m*), 8.86 (1H, t), 9.25 (1H, br s), 11.06 (1H, s);

N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[2-(piperidin-4-ylamino)-thiazol-4-yl]-benzamide (Compound 396); NMR (in DMSO-d₆): δ 8.23-7.76 (m, 6H), δ 7.24 (s, 1H), δ 4.0 (d, 2H), δ 3.82 (s, br, 1H), δ 3.6-2.8 (m, 43H), δ 2.28 (s, 8H), δ 2.2-1.14 (m, 10H); MS: H⁺ = 465.0;

4-(4-[4-[1-(Cyanomethyl-carbamoyl)-cyclohexylcarbamoyl]phenyl]-thiazol-2-ylamino)-piperidine-1-carboxylic acid ethyl ester (Compound 397);

20 (S)-4-Methyl-2-[4-(4-morpholin-4-yl-phenyl)-thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide (Compound 398);

(S)-4-Methyl-2-[4-(4-pyrrolidin-1-yl-phenyl)-thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide (Compound 399);

25 (S)-4-Methyl-2-[4-(3-phenylsulfonylureidophenyl)thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide (Compound 400);

(S)-4-Methyl-2-[4-[3-(3-phenyl-ureido)-phenyl]-thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide (Compound 401);

(S)-4-Methyl-2-(4-[3-[3-(4-phenoxy-phenyl)-ureido]-phenyl]-thiazol-2-ylamino)-pentanoic acid cyanomethyl-amide (Compound 402);

30 (S)-4-Methyl-2-(4-[3-[3-((R)-1-phenyl-ethyl)-ureido]-phenyl]-thiazol-2-ylamino)-pentanoic acid cyanomethyl-amide (Compound 403);

N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-(2-pyridin-4-yl-thiazol-4-yl)-benzamide (Compound 404); NMR (in DMSO-d₆): δ 8.78 (d, 2H), δ 8.55(s, 1H), δ 8.22 (m, 1H), δ 8.15(d, 2H), δ 8.11-8.05 (m, 3H), δ 7.99 (d, 2H), δ 4.0-4.06 (m, 2H), δ 3.69 (s, br, 3H), δ 2.11 (d, 2H), δ 1.75 (m, 2H), δ 1.52 (s, br, 5H), δ 1.26 (s, br, 1H); MS: M+ H⁺ = 446.4;

5 (3-[2-[(S)-1-(Cyanomethyl-carbamoyl)-3-methyl-butylamino]-thiazol-4-yl]-phenyl)-carbamic acid 3,4-dichloro-benzyl ester (Compound 405);

N-[[(S)-1-(1-Cyano-cyclopropyl-carbamoyl)-3-methyl-butyl]-4-(2-piperazin-1-ylmethyl-thiazol-4-yl)-benzamide (Compound 406);

10 N-[[(S)-1-(Cyanomethyl-carbamoyl)-3-methyl-but-3-enyl]-4-[2-(pyridin-4-ylamino)-thiazol-4-yl]-benzamide (Compound 407);







N-[[(S)-1-(Cyanomethyl-carbamoyl)-2-naphthalen-2-yl-ethyl]-4-[2-(pyridin-4-ylamino)-thiazol-5-yl]-benzamide (Compound 408);



















N-[[(S)-1-(Cyanomethyl-carbamoyl)-2-naphthalen-2-yl-ethyl]-4-[2-(pyridin-4-ylamino)-thiazol-4-yl]-benzamide (Compound 410); and















15 N-[(Cyanomethyl-carbamoyl)-dimethylamino-ethyl]-4-(2-pyridin-4-yl-thiazol-4-yl)-benzamide.







Proceeding by methods analogous to those set forth in this Application compounds of Formula I are provided which are comprised by the elements A, B and C listed in the following Table I.








TABLE 1








A		B		C	
A1		B1		C1	

A2		B2		C2	
A3		B3		C3	
A4		B4		C4	
A5		B5		C5	
A6		B6		C6	
A7		B7		C7	




A8		B8		C8	
A9		B9		C9	
A10		B10			
A11		B11			
A12		B12			
A13		B13			

A14					
A15					
A16					
A17					
A18					
A19					

A20					
A21					
A22					
A23					
A24					
A25					
A26					

A27					
A28					
A29					
A30					
A31					
A32					
A33					

5

A34					
A35					
A36					

5

While any combination of the elements A, B and C may comprise the compounds of the Invention, certain combinations are preferred. For example, the following combinations A1-B2-C1

10	A31-B2-C1	A15-B4-C1	A4-B12-C1	A31-B4-C2
	A26-B2-C1	A18-B4-C1	A5-B12-C1	A26-B4-C2
	A35-B2-C1	A19-B4-C1	A6-B2-C1	A35-B4-C2
	A22-B2-C1	A20-B4-C1	A9-B2-C1	A22-B4-C2
	A2-B2-C1	A21-B4-C1	A10-B2-C1	A2-B4-C2
15	A3-B2-C1	A1-B12-C1	A13-B2-C1	A3-B4-C2
	A4-B2-C1	A31-B12-C1	A15-B2-C1	A4-B4-C2
	A5-B2-C1	A26-B12-C1	A18-B2-C1	A5-B4-C2
	A6-B4-C1	A35-B12-C1	A19-B2-C1	A6-B12-C2
	A9-B4-C1	A22-B12-C1	A20-B2-C1	A9-B12-C2
20	A10-B4-C1	A2-B12-C1	A21-B2-C1	A10-B12-C2
	A13-B4-C1	A3-B12-C1	A1-B4-C2	A13-B12-C2

	A15-B12-C2	A5-B12-C5
	A18-B12-C2	A6-B2-C5
	A19-B12-C2	A9-B2-C5
	A20-B12-C2	A10-B2-C5
5	A21-B12-C2	A13-B2-C5
	A1-B2-C2	A15-B2-C5
	A31-B2-C2	A18-B2-C5
	A26-B2-C2	A19-B2-C5
	A35-B2-C2	A20-B2-C5
10	A22-B2-C2	A21-B2-C5
	A2-B2-C2	A1-B4-C5
	A3-B2-C2	A31-B4-C5
	A4-B2-C2	A26-B4-C5
	A5-B2-C2	A35-B4-C5
15	A6-B4-C2	A22-B4-C5
	A9-B4-C2	A2-B4-C5
	A10-B4-C2	A3-B4-C5
	A13-B4-C2	A4-B4-C5
	A15-B4-C2	A5-B4-C5
20	A18-B4-C2	A6-B12-C5
	A19-B4-C2	A9-B12-C5
	A20-B4-C2	A10-B12-C5
	A21-B4-C2	A13-B12-C5
	A1-B12-C5	A15-B12-C5
25	A31-B12-C5	A18-B12-C5
	A26-B12-C5	A19-B12-C5
	A35-B12-C5	A20-B12-C5
	A22-B12-C5	A21-B12-C5
	A2-B12-C5	
30	A3-B12-C5	
	A4-B12-C5	

EXAMPLE 17
Cathepsin B Assay

5 Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: *N,N*-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM (pH 6); polyoxyethylenesorbitan monolaurate, 0.05%; and dithiothreitol (DTT), 2.5 mM). Human
10 cathepsin B (0.025 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-FR-AMC (20 nMoles in 25 μ L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme
15 progress curves using standard mathematical models.

Compounds of the invention were tested according to the above-described assay and observed to exhibit cathepsin B inhibitory activity.

EXAMPLE 18
Cathepsin K Assay

20 Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: MES, 50 mM (pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM). Human cathepsin K
25 (0.0906 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-Phe-Arg-AMC (4 nMoles in 25 μ L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme progress
30 curves using standard mathematical models.

Compounds of the invention were tested according to the above-described assay

and observed to exhibit cathepsin K inhibitory activity.

EXAMPLE 19

Cathepsin L Assay

5 Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: MES, 50 mM (pH 5.5); EDTA, 2.5 mM; and DTT, 2.5 mM). Human cathepsin L (0.05 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 10 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. Z-Phe-Arg-AMC (1 nMoles in 25 μ L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme progress curves using standard mathematical models.

15 Compounds of the invention were tested according to the above-described assay and observed to exhibit cathepsin L inhibitory activity.

EXAMPLE 20

Cathepsin S Assay

20 Solutions of test compounds in varying concentrations were prepared in 10 μ L of dimethyl sulfoxide (DMSO) and then diluted into assay buffer (40 μ L, comprising: MES, 50 mM (pH 6.5); EDTA, 2.5 mM; and NaCl, 100 mM). Human cathepsin S (0.158 pMoles in 25 μ L of assay buffer) was added to the dilutions. The assay solutions were mixed for 5-10 seconds on a shaker plate, covered and incubated for 30 minutes at room temperature. 25 Z-Val-Val-Arg-AMC (9 nMoles in 25 μ L of assay buffer) was added to the assay solutions and hydrolysis was followed spectrophotometrically at (λ 460 nm) for 5 minutes. Apparent inhibition constants (K_i) were calculated from the enzyme progress curves using standard mathematical models.

30 Compounds of the invention were tested according to the above-described assay and observed to exhibit cathepsin S inhibitory activity.

EXAMPLE 21

Representative Pharmaceutical Formulations Containing a Compound of the Invention

5

ORAL FORMULATION

Compound of the Invention	10-100 mg
Citric Acid Monohydrate	105 mg
Sodium Hydroxide	18 mg
Flavoring	
10 Water	q.s. to 100 mL

INTRAVENOUS FORMULATION

Compound of the Invention	0.1-10 mg
Dextrose Monohydrate	q.s. to make isotonic
15 Citric Acid Monohydrate	1.05 mg
Sodium Hydroxide	0.18 mg
Water for Injection	q.s. to 1.0 mL

TABLET FORMULATION

20 Compound of the Invention	1%
Microcrystalline Cellulose	73%
Stearic Acid	25%
Colloidal Silica	1%.

25 The resulting tablets are useful for administration in accordance with the methods of this invention for treating or preventing a cathepsin mediated disease state, such as osteoporosis.

WE CLAIM:

1. A compound which is selected from a group consisting of:

5 *N*-(1*S*-Cyanomethylcarbamoyl-2-methylbutyl)-
4-(2-pyrid-3-ylthiazol-4-yl)benzamide;
N-(1*S*-Cyanomethylcarbamoyl-3-methylbut-3-enyl)-
4-(2-pyrid-3-ylthiazol-4-yl)benzamide;
10 *N*-(1-Cyanomethylcarbamoylcyclohexyl)-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;
N-[1-(4-cyanotetrahydropyran-4-ylcarbamoyl)cyclohexyl]-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;
N-(1-cyanomethylcarbamoylcyclohexyl)-
15 4-(2-morpholin-4-ylthiazol-4-yl)benzamide;
N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[2-(1-methylpyrid-3-yl)thiazol-4-yl]benzamide;
4-[2-(1-carbamoylmethylpyridin-3-yl)thiazol-4-yl]-*N*-(1*S*-cyanomethylcarbamoyl-
3-methylbutyl)benzamide;
20 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[2-(1-methylpyridin-4-ylamino)thiazol-4-yl]benzamide;
N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[2-(1-methylpyridin-4-yl)thiazol-4-yl]benzamide;
N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
25 4-[2-(1-allylpyrid-4-yl)thiazol-4-yl]benzamide;
ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl-
3-methylbutylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate;
ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl-
3-methylbutylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate;
30 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(4-pyrid-4-ylthiazol-2-ylamino)benzamide;

tert-butyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl}thiazol-2-yl}piperazine-1-carboxylate;

tert-butyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl]phenoxyethyl}thiazol-2-yl}piperazine-1-carboxylate;

5 *tert*-butyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl]piperidin-1-ylmethyl}thiazol-2-yl}piperazine-1-carboxylate;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(4-morpholin-4-ylmethylthiazol-2-ylamino)benzamide;

tert-butyl 4-{2-[4-(1*S*-cyanomethylcarbamoyl)-
3-methylbutylcarbamoyl]phenylamino}thiazol-4-ylmethyl}piperazine-1-carboxylate;

tert-butyl 4-(4-{4-[1*S*-(1-cyanocyclopropylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl}thiazol-2-yl)piperazine-1-carboxylate;

tert-butyl 4-(4-{4-[1*S*-(*N*-cyanomethyl-*N*-methylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl}thiazol-2-yl)piperazine-1-carboxylate;

15 *N*-[1*S*-(*N*-cyanomethyl-*N*-methylcarbamoyl)-3-methylbutyl]-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;

tert-butyl 4-(4-{4-[1*S*-(1-cyanocyclopropylcarbamoyl)-
3-methylbutylcarbamoyl]phenyl}thiazol-2-ylmethyl)piperazine-1-carboxylate;

tert-butyl

20 4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-yl}piperazine-
1-carboxylate;

tert-butyl

4-(4-{4-[1-cyanomethylcarbamoyl]cyclohexylcarbamoyl]phenyl}thiazol-2-ylmethyl)piperazine-1-carboxylate;

25 *N*-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-piperazin-1-ylthiazol-4-yl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
30 4-(2-piperazin-1-ylthiazol-4-ylmethoxy)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-

- 1-(2-piperazin-1-ylthiazol-4-ylmethyl)piperidine-4-carboxamide;
N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
 4-(4-piperazin-1-ylmethylthiazol-2-ylamino)benzamide;
N-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-
 5 4-(2-piperazin-1-yl-thiazol-4-yl)benzamide;
N-[1*S*-(*N*-cyanomethyl-*N*-methylcarbamoyl)-3-methylbutyl]-
 4-(2-piperazin-1-ylthiazol-4-yl)benzamide;
N-(1-cyanomethylcarbamoylcyclohexyl)-4-(2-piperazin-1-ylthiazol-4-yl)benzamide
 ;
 10 *N*-(1-cyanomethylcarbamoylcyclohexyl)-
 4-(2-piperazin-1-ylmethylthiazol-4-yl)benzamide;
 ethyl 4-{4-[4-(1*S*-cyanomethylcarbamoyl-
 3-methylbutylcarbamoyl)phenyl]thiazol-2-yl}piperazine-1-carboxylate;
N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
 15 4-benzylpiperazine-1-carboxamide;
 3-[3-(1-benzylpyrrolidin-3-yl)-3-methylureido]-*N*-(1*S*-cyanomethylcarbamoyl)-
 3-methylbutyl)benzamide;
N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
 4-(2-morpholin-4-ylethyl)piperazine-1-carboxamide;
 20 *N*-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
 4-(2-morpholin-4-ylethyl)piperazine-1-carboxamide;
 4-[3-(1-benzylpiperidin-4-yl)ureido]-*N*-(1*S*-cyanomethylcarbamoyl)-
 3-methylbutyl)benzamide;
 4-[3-(1-benzylpyrrolidin-3*S*-yl)-3-methylureido]-*N*-(1*S*-cyanomethylcarbamoyl)-
 25 3-methylbutyl)benzamide;
 4-[3-(1-benzylpyrrolidin-3*R*-yl)-3-methylureido]-*N*-(1*S*-cyanomethylcarbamoyl)-
 3-methylbutyl)benzamide;
N-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
 4-pyrimidin-2-ylpiperazine-1-carboxamide;
 30 *N*-[4-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-oxo-
 2-pyrrolidin-1-ylethyl)piperazine-1-carboxamide;

N-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-pyrimidin-2-ylpiperazine-1-carboxamide;

N-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-4-(2-oxo-
2-pyrrolidin-1-ylethyl)piperazine-1-carboxamide;

5 *N*-[3-(1*S*-cyanomethylcarbamoyl-3-methylbutylcarbamoyl)phenyl]-
4-benzylpiperazine-1-carboxamide;

3-[3-(1-benzylpiperidin-4-yl)ureido]-*N*-(1*S*-cyanomethylcarbamoyl-
3-methylbutyl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
10 4-(2-pyrid-4-ylamino)thiazol-4-ylbenzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-pyrid-4-ylthiazol-4-yl)benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-pyrid-2-ylamino)thiazol-4-ylbenzamide;

15 *N*-{4-[4-(1*S*-cyanomethylcarbamoyl-
3-methylbutylcarbamoyl)phenyl]thiazol-2-yl}isonicotinamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
20 4-(4-pyrid-4-ylpiperazin-1-yl)benzamide;

N-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;

N-(1*R*-cyanomethylcarbamoyl-3-methylbutyl)-
4-(2-morpholin-4-ylthiazol-4-yl)benzamide;

25 4-(2-pyrid-3-ylthiazol-4-yl)benzyl 1*S*-cyanomethylcarbamoyl-
3-methylbutylcarbamate;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-
4-[2-(4-methylpiperazin-1-yl)thiazol-4-yl]benzamide;

N-(1*S*-cyanomethylcarbamoyl-3-methylbutyl)-4-[*N*-methyl-
30 *N*-(4-pyrid-4-ylthiazol-2-yl)amino]benzamide;

tert-butyl

4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenoxy]methyl}thiazol-2-yl}piperazine-1-carboxylate;

tert-butyl 4-(4-{4-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutylcarbamoyl]phenyl}thiazol-2-ylamino)piperidine-1-carboxylate;

5 *N*-[1*S*-(1-cyanocyclopropylcarbamoyl)-3-methylbutyl]-4-(2-piperidin-4-ylaminothiazol-4-yl)benzamide;

tert-butyl 4-{4-[4-(1-cyanomethylcarbamoylcyclohexylcarbamoyl)phenyl]thiazol-2-ylamino}piperidine-1-carboxylate;

10 *N*-[1-(Cyanomethyl-carbamoyl)-2-methyl-butyl]-4-[2-(pyridin-3-ylamino)-thiazol-4-yl]-benzamide;

N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[2-(piperidin-4-ylamino)-thiazol-4-yl]-benzamide;

15 4-(4-{4-[1-(Cyanomethyl-carbamoyl)-cyclohexylcarbamoyl]phenyl}-thiazol-2-ylamino)-piperidine-1-carboxylic acid ethyl ester;

(*S*)-4-Methyl-2-[4-(4-morpholin-4-yl-phenyl)-thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide;

(*S*)-4-Methyl-2-[4-(4-pyrrolidin-1-yl-phenyl)-thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide;

20 (*S*)-4-Methyl-2-[4-(3-phenylsulfonylureidophenyl)thiazol-2-ylamino]-pentanoic acid cyanomethyl-amide;

(*S*)-4-Methyl-2-{4-[3-(3-phenyl-ureido)-phenyl]-thiazol-2-ylamino}-pentanoic acid cyanomethyl-amide;

25 (*S*)-4-Methyl-2-(4-{3-[3-(4-phenoxy-phenyl)-ureido]-phenyl}-thiazol-2-ylamino)-pentanoic acid cyanomethyl-amide;

(*S*)-4-Methyl-2-(4-{3-[3-((*R*)-1-phenyl-ethyl)-ureido]-phenyl}-thiazol-2-ylamino)-pentanoic acid cyanomethyl-amide;

N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-(2-pyridin-4-yl-thiazol-4-yl)-benzamide;

30 (3-{2-[(*S*)-1-(Cyanomethyl-carbamoyl)-3-methyl-butylamino]-thiazol-4-yl}-phenyl)-carbamic acid 3,4-dichloro-benzyl ester;

N-[(*S*)-1-(1-Cyano-cyclopropylcarbamoyl)-3-methyl-butyl]-4-(2-piperazin-1-ylmethyl-thiazol-4-yl)-benzamide;

N-[(*S*)-1-(Cyanomethyl-carbamoyl)-3-methyl-but-3-enyl]-4-[2-(pyridin-4-ylamino)-thiazol-4-yl]-benzamide;

5 *N*-[(*S*)-1-(Cyanomethyl-carbamoyl)-2-naphthalen-2-yl-ethyl]-4-[2-(pyridin-4-ylamino)-thiazol-5-yl]-benzamide;

N-[(*S*)-1-(Cyanomethyl-carbamoyl)-2-naphthalen-2-yl-ethyl]-4-[2-(pyridin-4-ylamino)-thiazol-4-yl]-benzamide; and

10 *N*-[(Cyanomethyl-carbamoyl)-dimethylamino-ethyl]-4-(2-pyridin-4-yl-thiazol-4-yl)-benzamide; and the *N*-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.

15 2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

20 3. The composition of Claim 2 which further comprises one or more active ingredient(s) selected from the group consisting of (i) a therapeutically effective amount of a bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof and (ii) a therapeutically effective amount of an estrogen receptor agonist or a pharmaceutically acceptable salt thereof.

25 4 The composition of Claim 3 wherein the bisphosphonic acid is selected from the group consisting of 1,1-dichloromethylene-1,1-diphosphonic acid, 1-hydroxy-3-pyrrolidin-1-ylpropylidene-1,1-bisphosphonic acid, 1-hydroxyethylidene-1,1-diphosphonic acid, 1-hydroxy-3-(*N*-methyl-*N*-pentylamino)propylidene-1,1-bisphosphonic acid, 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid, 3-(dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid, 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid, 2-pyrid-2-ylethylidene-1,1-bisphosphonic acid, 1-hydroxy-2-pyrid-3-ylethylidene-1,1-bisphosphonic acid, 4-chlorophenylthiomethylenebisphosphonic

30

acid and 1-hydroxy-2-(1*H*-imidazol-1-yl)ethylidene-1,1-bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof.

5 5 The composition of Claim 4 wherein the bisphosphonic acid is
5 1,1-dichloromethylene-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.

6. The composition of Claim 5 which comprises 1,1-dichloromethylene-
1,1-diphosphonate monosodium trihydrate.

10 7. A method of treating a disease in an animal in which cysteine protease
activity contributes to the pathology and/or symptomatology of the disease, which method
comprises administering to the animal a therapeutically effective amount of compound of
Claim 1; or a *N*-oxide derivative, prodrug derivative, protected derivative, individual
isomer or mixture of isomers or a pharmaceutically acceptable salt thereof.

15

8. The method of Claim 7 wherein the disease is osteoporosis.

9. The method of Claim 8 wherein the animal is a human.

20 10. The method of Claim 9 wherein the human is a post-menopausal woman.

11. The method of Claim 10 wherein the cysteine protease is cathepsin K.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68645 A3

(51) International Patent Classification⁷: **C07D 417/04**,
277/42, 417/12, 417/06, 277/28, 207/14, 211/58, 239/42,
207/27, 213/74, 295/215, 295/155, A61K 31/426,
31/4439, 31/454, 31/4468, 31/40, 31/505, 31/4015, 31/44,
31/495, A61P 19/10

Dan-Xiong [CN/US]; 722 Edgewater Boulevard #300,
Foster City, CA 94404 (US).

(21) International Application Number: PCT/US01/08332

(22) International Filing Date: 14 March 2001 (14.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/189,694 15 March 2000 (15.03.2000) US

(74) Agents: MONTGOMERY, Wayne, W. et al.; Axys Pharmaceuticals, Inc., 180 Kimball Way, South San Francisco, CA 94080 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): AXYS PHARMACEUTICALS, INC. [US/US]; 180 Kimball Way, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): PALMER, James, T. [US/US]; 131 Koch Road, Corte Madera, CA 94925 (US). SETTI, Eduardo, L. [CA/US]; 804 North Delaware Street, San Mateo, CA 94401 (US). TIAN, Zong-Qiang [CN/US]; 5029 Xavier Common, Fremont, CA 94555 (US). VENKATRAMAN, Shankar [IN/US]; 2979 Garden Creek Circle, Pleasanton, CA 94588 (US). WANG,

Published:

— with international search report

(88) Date of publication of the international search report:
7 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/68645 A3

(54) Title: N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS

(57) Abstract: The present invention relates to novel *N*-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and *N*-oxides thereof, their uses as therapeutic agents and the methods of their making.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/08332

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/04 C07D277/42 C07D417/12 C07D417/06 C07D277/28
C07D207/14 C07D211/58 C07D239/42 C07D207/27 C07D213/74
C07D295/215 C07D295/155 A61K31/426 A61K31/4439 A61K31/454

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 24460 A (NOVARTIS AG ET AL) 20 May 1999 (1999-05-20) the whole document ---	1-11
P,X	WO 00 55126 A (AXYS PHARMACEUTICALS, INC.) 21 September 2000 (2000-09-21) the whole document ---	1-11
P,X	WO 00 55125 A (AXYS PHARMACEUTICALS, INC.) 21 September 2000 (2000-09-21) the whole document -----	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

10 July 2001

Date of mailing of the international search report

11 10 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

ALLARD, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/08332

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/4468 A61K31/40 A61K31/505 A61K31/4015 A61K31/44 A61K31/495 A61P19/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 10 July 2001		Date of mailing of the international search report 11.10.2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer ALLARD, M

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/08332

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 7-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: **1-11 (all partially)**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-11 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-11 (all partially)

The terms "prodrug derivatives" and "protected derivatives" used in claim 1 of the present application are so unclear (Article 6 PCT) that a complete search for these aspects of the application is impossible. The search can therefore only be considered as complete for compounds recited in claim 1, the N-oxide derivatives, the individual isomers and mixtures of isomers, and the pharmaceutically acceptable salts thereof.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 (all partially)

Compounds of claim 1 recited in position 1-12, 14, 19-26, 30-34, 48-51, 54, 55, 57, 58, 60-65, 72, 74, 75, 77 and 78, i.e. N-(cyano-C-N-CO-C)benzamides substituted in position 4 by a substituted thiazol-4-yl, and their use.

2. Claims: 1-11 (all partially)

Compounds of claim 1 recited in position 13, 17, 18, 29 and 58, i.e. N-(cyano-C-N-CO-C)benzamides substituted in position 4 by a substituted thiazol-2-yl-amino, and their use.

3. Claims: 1-11 (all partially)

Compounds of claim 1 recited in position 15, 27 and 59, i.e. N-(cyano-C-N-CO-C)benzamides substituted in position 4 by a substituted thiazol-4-yl-methoxy, and their use.

4. Claims: 1-11 (all partially)

Compounds of claim 1 recited in position 16, 28, 35, 37, 38 and 42-46, i.e. N-(cyano-C-N-CO-C)piperidine-/piperazine-carboxamides, and their use.

5. Claims: 1-11 (all partially)

Compounds of claim 1 recited in position 36, 39-41 and 47, i.e. N-(cyano-C-N-CO-C)benzamides substituted in position 3 or 4 by a substituted ureido, and their use.

6. Claims: 1-11 (all partially)

Compounds of claim 1 recited in position 52 and 53, i.e. N-(cyano-C-N-CO-C)benzamides substituted in position 4 by a substituted piperazine, and their use.

7. Claims: 1-11 (all partially)

Compound of claim 1 recited in position 56, i.e. a carbamate derivative, and its use.

8. Claims: 1-11 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compounds of claim 1 recited in position 66-71 and 73, i.e. N-cyanomethyl-2-(substituted thiazol-2-yl-amino)-pentanamides, and their use.

9. Claims: 1-11 (all partially)

Compound of claim 1 recited in position 76, i.e. a N-(cyano-C-N-CO-C)benzamide substituted in position 4 by a substituted thiazol-5-yl, and its use.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/08332

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
W0 9924460	A	20-05-1999	AU 1487399 A	31-05-1999
			BR 9813197 A	29-08-2000
			CN 1278244 T	27-12-2000
			EP 1028942 A	23-08-2000
			NO 20002320 A	04-07-2000
			PL 340819 A	26-02-2001
			SK 6572000 A	09-10-2000
			TR 200001189 T	21-09-2000
			ZA 9810073 A	05-05-1999

W0 0055126	A	21-09-2000	AU 3746100 A	04-10-2000
			AU 3748600 A	04-10-2000
			W0 0055125 A	21-09-2000

W0 0055125	A	21-09-2000	AU 3746100 A	04-10-2000
			AU 3748600 A	04-10-2000
			W0 0055126 A	21-09-2000
